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To the Friends of the Department of Medicine:
“The only thing that is constant is change.”
What a year we have had! From new time slots for morning report, patient surges
in the hospital, moving the fellowship match to December and the addition of
Dim Sum Fridays, things are in a constant state of flux. The hallmark of a Jefferson
resident is the ability to evolve and adapt to the circumstances while continuing
to think of further changes to benefit our patients, colleagues and ourselves. I
cannot contain the pride I have in our residents and what they can achieve. With
more changes on the way with the Next Accreditation System from the ACGME,
launching the Milestones evaluations and potential changes in health care delivery
as Obamacare gets fully implemented, it is more important than ever to have a
spirit of innovation! It helps that we are led by the Fantastic Four—Christopher
Henry, Tasha Kouvatsos, Sanjay Linganna and Michael Tobin. Our chiefs are
tireless advocates for education and are creative problem solvers and have achieved
many things in their short tenure! I am so grateful for their efforts and have had an
amazing time working with them!
You will also notice some changes to the Forum this year. In addition to the
research abstracts, case reports, artwork and photography, you will notice some
new additions—medical app review and patient safety projects are among the
selected pieces included. The Editors, in the spirit of change and evolution, have
identified these areas as being useful, informative and necessary to the way we will
practice medicine now and in the future. Congratulations to the Editors and all the
contributors for another amazing edition! And thank you to all our contributors—
without you, the Forum would not exist!
Enjoy this edition of the Jefferson Forum!

Gretchen Diemer, MD, FACP
Assistant Professor of Medicine
Program Director Internal Medicine Residency
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We are proud to publish the 14th issue of the Jefferson Medicine Forum. The editorial
staff would like to acknowledge the support of Dr. Diemer in producing this year’s forum.
We appreciate your guidance and support in bringing this issue to print.
Over the years, the Medicine Forum has provided a unique opportunity for our
housestaff and medical students to not only share scholarly activities, but also to pursue
their interests outside of the medical field. This year, we are proud to announce the
addition of medical application reviews as well as an opinion piece on the use of opiates
in primary care – a controversial topic that often leads to heated debates. We have also
been fortunate enough to include interesting travel experiences, unique case reports, and
exciting review articles, along with some breathtaking photography and original cartoon.
We would like to thank our internal medicine residents and colleagues, for without their
endless enthusiasm and passion for medical knowledge, we could not have produced this
wonderful issue. We hope you enjoy this year’s forum with all of its new glitz and glamor.
Regards,
Rina Shah, MD and Mitul Kanzaria, MD
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Cerebrovascular Accident Caused by Embolic Atrial
Myxoma
Eugene Han, MD, Andrew Garrett, MD

Background
Atrial myxomas, the most common type of cardiac tumors, can
cause life-threatening complications. As most cardiac myxomas
are surgically curable, early diagnosis is crucial. Cardiac tumors
can present with cardiac and embolic manifestations, and should
be considered in the differential diagnosis of patients presenting
with such symptoms. In this case report, we describe a young,
healthy patient who presented with stroke symptoms secondary
to embolic atrial myxoma.

Case Presentation
A 45-year-old male with no past medical history presented with
an acute onset of dysarthria, described as garbled speech. He also
experienced weakness and heaviness of his right hand, which
impaired his ability to brush his teeth and write. He denied
left-handed or lower extremity weakness, head trauma, facial
droop, dysphagia, migraines, diplopia/visual changes, confusion,
or memory loss. He denied tobacco, alcohol, or drug use. Review
of systems was otherwise negative, although the patient reported
that whenever he participated in strenuous physical activity over
the past few years, he would become nauseated.

thorax revealed a hypoattenuating 3.7 x 2.4 cm lesion in the left
atrium. Transesophageal echocardiogram (TEE) confirmed a
large (5 x 3.2 cm), irregular, gelatinous mass, with frond-like,
mobile edges attached to the fossa ovalis, and broad 1 cm stalk.
This mass prolapsed into the mitral valve orifice during diastole,
likely representing a left atrial myxoma.

Treatment
Four days after presentation to TJUH, the patient underwent
robotic-assisted excision of the myxoma. There were no intraoperative complications, and post-procedure TEE revealed resolution
of the left atrial myxoma without mitral valvular insufficiency.
The patient required pressors and inotropic support for 2 days
post-operatively for persistent hypotension. He was discharged
home in stable condition on post-operative day #3.

Investigations
The patient initially presented to an outside hospital after his
symptoms persisted for over 24 hours. Computed tomography
(CT) of the head was negative for intracranial bleed and he
was discharged. While his dysarthria improved, he continued
to have weakness and went to another hospital for evaluation.
Brain magnetic resonance imaging (MRI) at the second hospital
showed two acute left basal ganglia infarcts. As part of the
stroke workup, he had an echocardiogram, which revealed a 5
cm left atrial myxoma. He was transferred to Thomas Jefferson
University Hospital (TJUH) for further management.
On presentation to the TJUH Cardiac Critical Care Unit (CCU),
the patient’s vital signs were as follows: temperature 98.2°F, blood
pressure 142/80 mm Hg, pulse 100 beats per minute, respiratory
rate 19 breaths per minute. Cardiac examination was notable for
a soft diastolic rumble heard best in the left upper parasternal
area. Neurological examination revealed minor dysarthria. The
remainder of the physical examination was normal. Complete
blood count and basic metabolic panel were within normal
limits, and electrocardiogram showed sinus rhythm. C-reactive
protein (CRP) was elevated to 7.9 mg/dL. Chest radiograph was
unremarkable. CT head showed left basal ganglia and corona
radiata hypodensities consistent with recent infarction. CT
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Figure 1. Three-chamber parasternal long axis view on echocardiogram with arrow indicating left atrial myxoma

Discussion
Myxomas, the most common type of benign primary cardiac
tumor, account for approximately one-third of benign tumors
of the heart.1-3 They occur across all age groups, more commonly
in women and during the third through sixth decades.1,4-7 90%
of cases are sporadic, while the remainder are transmitted in an
autosomal dominant fashion. This inheritance typically occurs
as part of the Carney syndrome complex that includes myxomas,
lentigines/pigmented nevi, and endocrine overactivity. 1,8-12
The NAME (nevi, atrial myxoma, myxoid neurofibroma,
and ephelides) and LAMB (lentigines, atrial myxoma, and

The Medicine Forum

blue nevi) syndromes likely represent subsets of the Carney
complex.1,13 While the genetic origin of the Carney complex is
unclear, patients frequently have inactivating mutations of the
PRKAR1A tumor-suppressor gene.1,13

istics of myxomas.1,2 In the past, cardiac catheterization and
angiography were routinely performed prior to excision; their
role has diminished in favor of noninvasive imaging due to the
additional risk of tumor embolization during catheterization.1,32

Most myxomas arise in the left atrium from the interatrial
septum near the fossa ovalis.4,14 They are gelatinous structures
comprised of myxoma cells in a glycosaminoglycan-rich
stroma, often pedunculated on a fibrovascular stalk.1,14,15 They
arise from multipotent mesenchymal cells that persist from
embryonic cardiac septation and have been found to produce
vascular endothelial growth factor (VEGF), which is implicated
in the early stages of tumor growth.13-16

Definitive treatment for a myxoma is surgical excision; medical
therapy is only indicated for management of concomitant CHF
and/or arrhythmias.1,33,34 Septal defects and/or valvular damage
that occur during surgery may require repair.33,34 A potential
complication of excision is fragmentation and embolization of
part of the tumor.33,34 While thrombolytic therapy is reasonable
for stroke secondary to blood clot emboli from cardiac myxomas,
it has little effect on emboli composed of actual tumor.35 Overall
post-surgical prognosis is excellent, with a 3% rate of operative
mortality.1,19,33,34 Recurrence is rare in sporadic cases (1-2%) and
usually due to inadequate resection; familial myxomas recur in
12-22% of cases and are likely due to multifocal lesions.1,2,19,27
Follow-up includes routine semi-annual echocardiography.
Screening of first-degree relatives is appropriate due to the
possibility of familial inheritance.1

Depending on location, myxomas can cause the signs and
symptoms of corresponding valvular disease; atrial myxomas
can mimic atrioventricular (AV) valve stenosis due to valve
obstruction, while ventricular myxomas can cause outflow
obstruction similar to subaortic or subpulmonic stenosis. 1,3
Diastolic murmurs result from obstruction of the filling
ventricle, while systolic murmurs arise when valve closure or
outflow is interrupted. 3 The characteristic “diastolic tumor
plop,” a low-pitched sound during early to mid-diastole, is
thought to represent the physical impact of the tumor hitting
the AV valve or ventricular wall.1 Repetitive trauma to the valve
may also cause damage and regurgitation due to a “wrecking
ball” phenomenon.17 Congestive heart failure (CHF) may result
from obstruction of cardiac flow and/or impaired contractility
from direct invasion of the myocardium (myocardial damage
may also cause arrhythmias, heart block, pericardial effusion
or tamponade). 2,18,19 Symptoms may provide a clue to the
tumor’s location: left-sided tumors may present with dyspnea
on exertion, orthopnea or flash pulmonary edema; right-sided
tumors may present with syncope, sudden death or right
heart failure. 2, 18-21 Of note, these symptoms can be sudden
and/or positional due to the effect of gravity on the tumor’s
position.1,2,18,19 Fragments of myxomas may embolize and cause
signs of peripheral or pulmonary emboli, as well as fever, weight
loss, malaise, arthralgias, rash, digital clubbing, and Raynaud’s
phenomenon.1,2,22-28 Laboratory abnormalities associated with
myxomas include anemia, leukocytosis, thrombocytopenia/
cytosis, elevated erythrocyte sedimentation rate (ESR) and
CRP.1,2,22 Rarely, myxomas may become infected; the incidence
of cerebral and systemic emboli from infected myxomas is
greater than that from non-infected myxomas.29 Management of
these patients is often complicated by bacteremia, septic shock,
disseminated intravascular coagulation (DIC), multi-organ
failure, and cerebral infarction.30
Echocardiography is useful in diagnosing myxomas; tumor size,
shape, and attachment can be assessed, all of which assist in
surgical planning for excision.1,3,18,31 TEE offers superior imaging
compared to transthoracic echocardiography (TTE) owing to
the proximity of the esophagus to the heart and use of high
frequency transducers.31 Cardiac CT and MRI offer noninvasive
imaging options that can also help evaluate the character-

Key Points
Although an uncommon cause of stroke, cardiac myxoma should
be considered in the differential diagnosis. Definitive treatment
is surgical resection, which offers excellent cure rates with rare
recurrence and low mortality. Medical management is supportive.
Once a cardiac myxoma has been identified, arrangements for
surgical resection should be made immediately.
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Newly Diagnosed AIDS with Multiple Opportunistic
Infections Despite a Recent Negative Rapid HIV Test
Soham Vakil, MD, Rene Daniel, MD, PhD, William Short, MD, MPH

Background
Human Immunodeficiency Virus (HIV) is a fairly prevalent
disease in the United States, with an estimated 1 million
persons infected with HIV-1.1 Despite a decrease in Acquired
Immunodeficiency Syndrome (AIDS), the prevalence of HIV
is increasing, which has led to recent changes in HIV testing
guidelines.2 Newly diagnosed patients should ideally be linked
to care and receive intervention and antiretroviral therapy
(ART) allowing them to maintain a near normal life expectancy.

Case Presentation
The patient is a 23-year-old African American male with no
significant past medical history. He presented to the emergency
department (ED) with fevers, weakness, worsening right-sided
chest pain, and shortness of breath associated with a productive
cough. When he presented with similar symptoms two
weeks ago, he was treated for pneumonia with azithromycin.
Symptoms initially improved but then worsened five days
prior to returning to the ED. He had odynophagia for the last
three weeks causing him to avoid solid foods. Additionally, he
reported loss of vision in his right eye for two months which
started as blurriness but progressed to only appreciating light
versus dark. Left eye vision was intact.
He took no chronic medications and denied drug allergies.
Surgical and family history was non-contributory. He
rarely drank alcohol and denied tobacco or drug use. He is
homosexual and became sexually active at the age of fourteen
with inconsistent condom use. He reported a negative rapid
HIV test at a local clinic one month ago and his last sexual
contact was three months prior to presentation.

perihilar interstitial infiltrates, more progressed compared to
two weeks prior. A rapid HIV test in the ED was positive. CT
of the chest showed bilateral patchy, confluent areas of ground
glass opacity with perihilar predominance involving all lobes
relatively sparing the bases.

Differential Diagnoses
Given his newly diagnosed HIV infection, differential
diagnosis included community acquired pneumonia (CAP),
Pneumocystis jirovecii pneumonia (PCP), opportunistic viral
pneumonia, fungal pneumonia, Mycobacterium infection. His
odynophagia was thought to be secondary to esophagitis, likely
from Candida albicans, Cytomegalovirus (CMV), or Herpes
Simplex Virus (HSV). Possible causes of vision loss included
CMV retinitis, toxoplasma retinochoroiditis, and Varicella
Zoster Virus Retinitis.

Treatment
Infectious Disease (ID) was consulted, and he was started on
empiric moxifloxacin to cover for CAP, including atypical
pathogens. He was also started on IV pentamidine for possible
PCP. Pentamidine was used secondary to a hospital shortage of
IV trimethoprim-sulfamethoxazole (TMP-SMX). Additionally,
he was received IV ganciclovir to empirically treat CMV
retinitis and possible CMV or HSV esophagitis. He was started
on fluconazole to treat thrush and possible candida esophagitis.
His rapid HIV antigen/antibody combination test was positive
and confirmed by Western Blot. His CD4 count was 41 cells/
mcL, establishing a diagnosis of AIDS. The genotype revealed
wild type HIV-1 with a viral load of 3.68 million copies/mL.

On physical exam, the patient’s vitals were temperature of
97.6°F, heart rate 101 bpm, blood pressure 133/76 mmHg,
respiratory rate 18 bpm, pulse oximetry 98% on room air. Head
and neck exam revealed oral thrush and a nonreactive right
pupil. Confrontation of visual fields revealed lack of vision
in all four quadrants of the right eye. Eyes were anicteric and
without conjunctival injection. Cardiovascular exam revealed
mild tachycardia but was otherwise normal. Lungs were clear
to auscultation. Abdomen exam was unremarkable. He had no
lymphadenopathy and the rest of his physical exam was normal.

Upon admission, Ophthalmology performed a dilated eye exam,
which revealed total retinal necrosis of the right eye. There was
necrosis and fibrosis of the macula, peripheral retinal necrosis,
as well as “frosted branch” retinitis and hemorrhage with
“brush fire” appearance. These exam findings combined with
a CD4 count less than 50 cells/mcL were consistent with CMV
retinitis, and visual prognosis was poor given diffuse necrosis
that progressed for two months. Exam of the left eye revealed
mild cotton wool spots which could represent either early CMV
retinitis versus HIV retinopathy. For induction treatment, he
was continued on IV ganciclovir (eventually changed to oral
valganciclovir).

Lab work was significant for a hemoglobin of 11.6 g/dL,
mean corpuscular volume of 78 fL, RDW 15.5%, and lactate
dehydrogenase of 581 IU/L. Comprehensive metabolic panel
was within normal limits. Chest X-ray revealed patchy bilateral

His respiratory symptoms slowly began to improve with
antibiotics. Bronchoscopy revealed minimal non-purulent
secretions. Cultures from bronchoalveolar lavage (BAL) were
negative for acid fast bacilli, respiratory viruses (including

Investigations
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influenza A, B), and bacteria. Fungal culture showed light
growth of Candida albicans, and cytology with silver stain was
positive for PCP. Treatment was narrowed to IV pentamidine
until he was able to tolerate oral treatment doses of TMP-SMX.
He was maintained on fluconazole for thrush. For his esophagitis,
endoscopy was deferred as he was already on fluconazole for
Candida infection as well as IV ganciclovir for treatment CMV
retinitis, which would also treat concomitant CMV or HSV
esophagitis.

Outcome And Follow-Up
His symptoms began to improve significantly. After his
esophagitis resolved, he was transitioned to oral medications to
complete treatment of his multiple opportunistic infections. He
was discharged from the hospital to finish treatment at home and
follow up with his ID physician later that week to initiate ART.

Discussion
This case illustrates that despite improved testing techniques,
it is still possible for patients to present with new diagnoses of
HIV in late stages. Moreover, false negative screening tests are
still possible, and patients can present with new HIV/AIDS via
multiple simultaneous opportunistic infections. Additionally, it
reinforces treatment of various opportunistic infections.
This patient presented with a CD4 count of 41 cells/mcL but
had a negative HIV test one month prior. This represents either
seronegative chronic HIV infection or chronic infection with a
false negative enzyme immunoassay (EIA) and failure to detect
the antibody. Alternatively, it may be an atypical instance of
acute infection prior to seroconversion with the CD4 count
falling dramatically low before recovering to the typical 600-700
cells/mcL.3 The latter scenario of an acute infection would place
the primary HIV infection at roughly 6 weeks prior to admission,
which is less likely since visual symptoms began at least 8 weeks
prior to admission.3,4 A final possibility is fulminant HIV. Given
his long standing risk factors and several months of visual
symptoms (which occur at advanced immunosuppression), he
likely had chronic HIV that was not detected.
The CDC recommends use of rapid HIV tests so more patients
obtain their results.4 Many outpatient facilities use the third
generation EIA, capable of detecting HIV antibodies as early as
three weeks after infection.5,6 All commercially used tests have
excellent sensitivities (>99%) for detection of HIV antibodies,
and many can detect them even before the traditional Western
blot confirmation test can, yielding pseudo-false positive results
that require repeat testing. 5 Although these screening tests
have excellent performance, their sensitivities are not 100%.
There are several reported incidences of false negative EIA
tests secondary to immune dysfunction and impaired humoral
response, delay to seroconversion following initiation of ART,
as well as fulminant HIV infection.7-11
8

This case demonstrates the need for better access to care and
earlier intervention. Unfortunately, this young man’s retinal
necrosis was so advanced that he will likely never recover vision
in his right eye. Had his HIV been diagnosed earlier, his multiple
infections and vision loss may have been prevented. Due to an
increasing prevalence of HIV, the 2006 revised CDC guidelines
for HIV testing recommend screening for patients in all settings
in an opt-out fashion, at least annual testing for those at higher
risk, and screening to become overall more routine and not
require separate consent.4 A new US Preventative Services Task
Force (USPSTF) draft recommends screening all adults age 15
to 65, with more frequent testing in high risk individuals.12
PCP usually occurs in HIV patients with CD4 counts less than 200
cells/mcL. Patients typically develop fever, progressive dyspnea,
nonproductive cough, chest discomfort, and uncommonly
blebs, cysts, and pneumothorax. Severe cases are characterized
by hypoxemia. Imaging usually demonstrates diffuse, bilateral,
interstitial infiltrates. Diagnosis requires induced sputum
or BAL histopathologic confirmation. Treatment of choice
is TMP-SMX orally or parenterally in severe cases and when
patients cannot tolerate oral medications. In cases of drug
intolerance, IV pentamidine is the preferred treatment. Patients
with moderate-severe disease, PaO2 less than 70 mmHg or A-a
gradient > 35 mmHg should receive corticosteroids. Treatment
should last 21 days, then TMP-SMX should be decreased to
prophylactic dosing. Additionally, ART should be initiated
within two weeks if not already started.13
CMV disease is usually in patients with HIV and CD4 counts
less than 50 cells/mcL. CMV retinitis is a necrotizing retinitis
that often begins unilaterally, but without treatment, viremic
dissemination causes bilateral retinitis. Symptoms include
scotoma, floaters, and visual field defects. Visual acuity
decreases with central retinal lesions. Diagnosis is made by an
ophthalmologist during a dilated eye exam with recognition of
characteristic fluffy yellow-white retinal lesions and possible
intra-retinal hemorrhage. Treatment for mild disease is typically
oral valganciclovir. Moderate-severe disease is treated with
intraocular implant of ganciclovir plus oral valganciclovir or
iv ganciclovir alone. Induction phase is 14-21 days followed
by maintenance with lower dose valganciclovir and regular
ophthalmologic exams to detect relapse or immune recovery
uveitis. Maintenance can be discontinued after six months of
sustained quiescent retinitis and CD4 counts over 100 cells/
mcL.13
Esophagitis is characterized by odynophagia and retrosternal
pain. In HIV patients, it is reasonable to empirically treat
for candida, especially with the presence of oral thrush, and
perform endoscopy if symptoms do not improve after 3-5
days. Treatment of choice for candida esophagitis is systemic
treatment for 14-21 days with fluconazole. CMV esophagitis
is diagnosed by endoscopy and biopsy and is treated with IV
ganciclovir or oral valganciclovir if tolerated for 21 days or until
symptoms resolve. HSV esophagitis is treated with IV acyclovir
(orally if tolerated) for 14-21 days.13
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Key Points
In accordance with revised guidelines, HIV testing should be
routine, particularly in patients who are high risk. Clinical
judgment should increase index of suspicion for further HIV
testing such as nucleic acid amplification, as there are rare cases
of seronegative AIDS as wells as false negatives despite excellent
sensitivities.
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An Interesting Case Report of Diabetic Myonecrosis
Manjula Nagaraja, MD and Jim Zhang, MD

Case Presentation
A 49-year-old male with a history of ischemic cardiomyopathy,
New York Heart Association class II heart failure with an
ejection fraction of 35% status post biventricular implantable
cardiac defibrillator (ICD), end stage renal disease on dialysis,
diabetes mellitus II, and pancreatitis complicated by pseudocyst
presented with a sudden onset of left thigh pain with a palpable
mass. He denied trauma to the site, numbness, tingling, weakness,
fevers, or chills. Review of systems was otherwise negative. Vital
signs at presentation were as follows: temperature 98.8°F, pulse
77 beats per minute, blood pressure 150/88 mm Hg, respiratory
rate 18 breaths per minute, and oxygen saturation of 96% on 2
liters of nasal cannula. He was notably uncomfortable on exam.
The left thigh was edematous on the lateral side and there was
tenderness over the distal, lateral portion of the anterolateral left
thigh. No tenderness in the calf was noted. He had full range of
motion at the hip, ankle, and knee. Straight leg test was negative
and pinprick sensation was decreased.
Laboratory tests revealed leukocytosis with a white count of
23.1, slight anemia with a hemoglobin of 9.4. Chem 7 revealed
BUN of 33 and creatinine of 4.1. Hemoglobin A1c was 8.0 and
CPKwas 82. Coags were normal but ESR was elevated at 98.
Radiographic studies included x-ray of the left femur, which
revealed no fracture or dislocation. Chest x-ray on admission
demonstrated a right dialysis catheter, low lung volumes with
mild background pulmonary edema and cardiomegaly. Lower
extremity ultrasound was negative for deep vein thrombosis.
MRI of the left thigh was not obtained due to his ICD. CT
scan of the left thigh showed heterogeneously decreased
enhancement of the quadriceps particularly within the vastus
lateralis; skin thickening with infiltration of the subcutaneous
fat, possibly representing cellulitis in the appropriate clinical
setting; diffuse atherosclerotic disease with moderate stenoses
of the left femoral artery at the level of the adductor hiatus and
the left popliteal artery (Figure 1).

Differential Diagnosis
The patient presented with a left thigh mass containing
inflammatory and infectious features. The differential includes:
superficial and deep vein thromboses, pyomyositis, myositis
ossificans, traumatic muscle rupture, muscle hemorrhage,
fasciitis, osteomyelitis, abscess, soft tissue neoplasm (primary
lymphoma or sarcoma), granulomatous lesions involving TB
or sarcoid, calciphylaxis. A rare but important diagnosis on the
differential should include diabetic myonecrosis, which is what
our patient had.
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Figure 1. CT Scan of Left Thigh
Biopsy showed increased variation in the fiber diameter,
increased interstitial fibrosis, and relative type II fiber atrophy.
There was no evidence of a neurogenic process or malignancy.

Discussion
Skeletal muscle infarction is a rare and unusual complication
of diabetes mellitus. Most patients have advanced end organ
damage by the time of presentation. Typical clinical presentation
of diabetic myonecrosis includes abrupt onset of pain and
swelling in the affected muscle. Patients have subsequent
partial resolution and appearance of a palpable painful mass.
The quadricep muscle group is most commonly affected; calf
involvement is rare. Bilateral involvement has been reported in
a few cases. The muscles most frequently affected are the vastus
lateralis (24%) and vastus medialis (22%).1
Most laboratory values are nonspecific. Elevated body
temperature was not always reported. Creatinine kinase
enzymes were often normal in reported cases. About one-third
of the patients had leukocytosis; three quarters had ESR > 50.2 Of
known cases, the majority (75%) had a hemoglobin A1C greater
than 7%, suggesting poor glycemic control. An ultrasound should
be performed to evaluate for deep vein thrombus and abscess
collection. MRI is most sensitive and is the diagnostic modality
of choice. In approximately 57% of cases, however, diabetic
myonecrosis was confirmed by biopsy. Currently, because of
complications of biopsy in diabetic patients, physicians tend to
eschew invasive methods. Biopsy should be reserved for cases
with an atypical presentation.

The Medicine Forum

MRI can show an increased signal from the affected muscle
area in T2 images that are hypointense areas on T1 images.
Other features can include diffuse enlargement with foci of
hemorrhage. Pathologic features most commonly showed
muscle fiber necrosis and inflammatory infiltrates. Findings
at later stages include replacement of necrotic muscle fibers
by fibrous tissue. Microvascular abnormalities can include
luminal narrowing and intramural calcifications or perhaps
fibrinoid occlusion. The etiology of diabetic myonecrosis
remains controversial. There are two proposed mechanisms,
microvascular disease and hypercoagulability. Extensive
arterial occlusive disease has been identified in many patients.
The theory suggests diabetic microangiopathy and/or arteriosclerosis lead to ischemia of muscle, which results in an intense
inflammatory response, edema and hyperemia. Some authors
suggest that acquired hypercoagulability might be to blame.
This latter theory is supported by detection of antiphospholipid
antibodies in several cases.
Optimal treatment of diabetic myonecrosis is uncertain.
Most patients received bed rest and analgesics. Therapeutic

modalities that may be beneficial include antiplatelet agents and
anti-inflammatory agents. Some authors recommend anticoagulation therapy. Short term prognosis is good as symptoms
usually resolve within 8 to 12 weeks.3 Approximately 42-48%
of cases re-occur usually on the same side. Contralateral
recurrence is associated with a poorer prognosis. Most of the
patients diagnosed with diabetic myonecrosis will eventually die
from long-term complications of diabetes. The mean mortality
rate was 10% within two years from diabetic myonecrosis onset.4
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Overview of Diuretic Strategies in Edematous States
Kedar Mahajan, MD

Introduction
Considering potential physiologic causes of volume overload in
clinical practice, such as heart failure, renal failure, nephrotic
syndrome, or portal hypertension, may yield insight into
directing therapy beyond switching from oral to intravenous
diuretic therapy. Appropriate oral therapies that achieve effective
diuresis may reduce costs, address shortages of intravenous loop
diuretics, reduce the need for unnecessary inpatient admissions
by facilitating outpatient management, allow earlier optimization
of outpatient regimens, and decrease the length of hospital stay.

Congestive Heart Failure
Decreased responsiveness to oral diuretics in either high or
low output heart failure has been described. Goldman’s Cecil
Medicine identifies factors such as gut edema, hypotension,
reduced renal blood flow, and adaptive changes in the nephron.1
Bowel wall edema from elevated systemic venous pressures in
heart failure may decrease bioavailability of diuretics while
increased renal afterload from venous congestion and intrinsic
renal compromise from interstitial pressures impairs diuresis.2
“Adaptive changes” are seen in long term loop diuretic use and
include hypertrophy and hyperplasia of the distal convoluted
tubule cells and increased Na+/Cl- - cotransporter activity
which both contribute to increased sodium reabsorption.3 This
adaption is partially addressed by blocking the reabsorption with
thiazide/thiazide-like (e.g. hydrochlorothiazide or metolazone)
diuretics and decreasing Na+/Cl- - cotransporter upregulation
by inhibiting effects of aldosterone (e.g. spironolactone or
eplerenone). 1, 3
Optimal outpatient management of diuresis in heart failure is
often difficult. Doubling the oral dose of diuretics (furosemide,
torsemide, and metolazone) does not affect left ventricular
systolic or diastolic function, has been shown to improve
symptoms and 6-minute walk distance after a 24 day endpoint.4
Detrimental effects of high-dose diuretics in systolic dysfunction
have be associated with increased mortality raising controversy,
but confounding factors such as diuretic resistance or heart
failure severity have made these links uncertain.5 The superior
pharmacodynamic profile of toresemide (see Table 1) and its
anti-aldosterone and vasorelaxation effect likely contributes to
its better performance in improving left ventricular function,
reduction of mortality, frequency/duration of heart-failure
related hospitalization, quality of life, exercise tolerance and
New York Heart Association functional class compared with
furosemide.6, 7 Synergy of loop-diuretics with potassium sparing
or thiazide diuretics is efficacious in persistent edematous states.8
Additionally, inadequate tissue perfusion, signaled by increasing
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blood urea nitrogen or serum creatinine, can be addressed
during diuresis in heart failure with inotropes or vasodilators.

Renal Disease
Patients with renal insufficiency benefit from loop diuretics
since they retain their utility at a creatinine clearance (CrCl) < 5
mL/min while distal tubule diuretics lose their efficacy at a CrCl
< 40 mL/min. However, thiazides and thiazide-like diuretics
(e.g. metolazone), provide synergistic effects when administered
thirty min prior to a loop diuretic to inhibit compensatory distal
tubular reabsorption, which avoids having to increase loop
dosages and limits long-term exposure to high-dose diuretics.9, 10
Higher doses of diuretics are required with a fall in the glomerular
filtration rate, whether in chronic kidney disease (CKD), acute
kidney injury, or hypoperfusion states. Drug secretion into the
lumen of the nephron is diminished with retention of competing
anions in renal failure and fewer functioning nephrons limit the
maximal response of the drug. Moderate CKD can require 80 mg
of intravenous furosemide (or bumetanide 2-3 mg, or torsemide
20-50 mg) while 200 mg may be required with severe CKD (or
bumetanide 8-10 mg, or torsemide 50-100 mg).11
Renal tubular secretion of furosemide is typically normal in
nephrotic syndrome but since the diuretic is bound to urinary
albumin, the lack of active drug blunts the diuretic response. If
urinary albumin exceeds 4 g/L, 50-66% of the drug is bound to
albumin and inactive.12 Appropriate measures include increasing
doses, frequency, and using thiazides in conjunction with
loop-diuretics. Avoidance of renal vasoconstriction mediated by
non-steroidal anti-inflammatory drugs (NSAIDs) also improves
diuretic responsiveness.

Portal Hypertension
Limited cardiac output in heart failure decreases loop diuretic
secretion into the tubular lumen from decreased renal perfusion,
while cirrhosis through renal vasoconstriction. The mainstay
diuretic in managing moderate-volume ascites in cirrhosis is
either spironolactone (50-200 mg/day) or amiloride (5-10 mg/
day) with low doses of furosemide (20-40 mg day) to supplement
natriuresis if peripheral edema is present. The recommended
daily weight loss in these patients without and with peripheral
edema is up to 1 lb and 2 lbs respectively to prevent pre-renal
failure. 13 Patients with large-volume ascites and marked
abdominal discomfort impairing activities of daily living can
ideally undergo therapeutic paracentesis or attempt maximum
doses of spironolactone (400 mg/day) and furosemide (160
mg/day). These patients typically present with urinary sodium
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Table 1. Pharmacodynamics and kinetics of common diuretics
Onset (min)
Furosemide (PO)

30 – 60

Furosemide (IV)

5

Peak (hours)
1–2

Duration (hours)
6–8

τ½ (hours)

Bioavailability (%)

0.5 – 2*

47 – 64

2

Bumetanide (PO)

10

1

4–6

1 – 1.5

59 – 89

Torsemide (PO)

60

1–2

6–8

3.5†

80

Ethacrynic acid (PO)

30

2

12

2–4

Metolazone (PO)

60

≥ 24

20

48-72

1.3‡

Spironolactone (PO)

3–4

* End-stage renal disease: half-life (τ½) increases to 9 hours
† Cirrhosis: half-life (τ½) increases to 7-8 hours
‡ Active metabolites have the following half-lives (τ½): canrenone: 10-23 hours; 7-alpha-spirolactone: 7-20 hours
Loop diuretic equivalency: furosemide 40 mg PO = furosemide 20 mg IV = bumetanide 1 mg PO/IV = torsemide 20 mg PO/IV = ethacrynic acid 50 mg PO
(sulfonamide alternative)
(Adapted from Lexi-Comp)

< 10 mM and normal free-water excretion and serum sodium.
When free-water excretion is impaired, dilutional hyponatremia
develops spontaneously or with increased fluid intake.
Patients with anasarca can have 2-3 L of fluid removed daily
without reduction in plasma volume whereas patients with
isolated ascites (no peripheral edema), can only have 300-500
mL/day of ascitic fluid mobilized daily without risking
azotemia.14 The azotemia will improve after ceasing diuresis and
fluid repletion whereas hepatorenal syndrome, often mistakenly
linked to diuretic use, will continue to worsen. Similar to patients
in acute or chronic heart failure, rapid diuresis in cirrhotic
patients leads to decreased cardiac output. Diuretic-resistant
ascites is defined by either inability to mobilize ascites despite
sodium restriction (24-hour urine with < 78 mEq sodium or a
random urine sodium < urine potassium) and maximum oral
diuretics (spironolactone 400 mg/day and furosemide 160 mg/
day) or prohibitive diuretic-related complications (progressive
azotemia, hepatic encephalopathy, or progressive electrolyte
imbalance) in the absence of NSAIDs.15 Ceasing beta-blockers,
angiotensin receptor blockers, or angiotensin converting enzyme
inhibitors, can improve blood pressure, tissue perfusion, renal
function, and diuretic responsiveness.

Discussion
Compounding renal insufficiency with reduced intestinal
motility, perfusion, mucosal edema and tolerance to oral
diuretics may also project a need for intravenous therapy;
however, awareness of the pharmacokinetics and dynamics of
diuretics will often provide solutions.16 All diuretics need to
attain a minimal rate of tubular excretion before a response is
attained. Minimal response at a given dose indicates the dose
was effective in achieving the minimal rate but the effect was

short-lived; a twice daily regimen can achieve the desired urine
output. However, no response following a diuretic suggests
doubling the dose (maximum furosemide dose 320-400 mg PO
or 160-320 mg IV) for diuresis.11 Between the minimum drug
excretion rate required for initiating diuresis and a plateau where
further drug excretion does not produce additional output, lies
the critical curve where drug excretion correlates to the extent
of naturesis.
Tolerance exists even with consecutive multiple intravenous doses
of furosemide in healthy individuals where naturesis/diuresis
decreases with compensatory increased renin and decreased
atrial natriuretic peptide.17 Outpatient diuretic tolerance can
be compounded by renal compensatory mechanisms or an
impaired natriuretic response to furosemide if on a low sodium
diet. 18 A few weeks of a diuretic dose will activate sodium
retaining forces (e.g. renin-angiotensin II-aldosterone, norepinephrine, or reduction in system blood pressure) to achieve
steady-state in sodium intake and excretion.19 However, poor
adherence to sodium restriction on the other hand will prevent
net fluid loss despite adequate diuresis; greater than 100 mEq
sodium (2 g sodium = 88 mEq) in a 24-hour urine collection
suggests non-compliance.20
Approaches that use higher doses of the drug, increased
frequency, or synergy with other diuretics are required to
overcome sodium retention. Substantial responses in diuretic
naïve patients are likely due to a lack of these adaptations. Acute
decompensated patients on outpatient doses of furosemide doses
≥ 120 mg/day benefit from initial bolus doses inpatient while
outpatient regimens with lower doses responded better to initial
continuous dosing.21 Other loop diuretics such as bumetanide
and toresemide boast of superior bioavailability (Table 1) and
can be considered first-line agents over furosemide in certain
cases. In heart failure patients, toresemide has been shown to
decrease left-ventricular remodeling, rates of hospitalization,
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and mortality over furosemide.6 When compared to furosemide,
bumetanide was more effective in reducing edema in patients
with nephrotic syndrome and dyspnea in heart failure.6 Certain
localized edematous states secondary to venous insufficiency,
moderate-severe lymphedema, or malignant ascites require
caution against depleting plasma volume when using diuretics.14
Given the multifactorial causes of diuresis failure, exploring the
nature of the edema state, utilizing a different diuretic agent or
considering an additional agent, changing the route, frequency
(Table 1), or the dose, can be attempted. The bioavailability of
a diuretic will influence the dose required for a response while
the plasma half-life will determine frequency of administration.
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A Benign Cause of Widened Mediastinum: A Case of
Mediastinal Lipomatosis
Natasha Fonseka, MD, Ewa Ruel, MD

Introduction
We report a patient with a widened mediastinum secondary to
a rare and benign condition known as mediastinal lipomatosis
(ML). ML is caused by accumulation of adipose tissue within the
mediastinum. Case reports associate ML with obesity, diabetes,
Cushing’s syndrome, steroid use while other cases remain
idiopathic.1-4 We report a patient with Glioblastoma Multiforma
(GBM) on chronic steroids, who was found to have ML on
imaging despite lack of obesity or Cushing’s syndrome. This
case provides significant educational benefit in approaching a
patient with a widened mediastinum.

Case Presentation
A 59-year-old male with a history of recurrent GBM status post
stereotactic radiation and ongoing chemotherapy presented to
the hospital with lethargy, altered mental status and expressive
aphasia consistent with ongoing progression of his malignancy.
The patient was not obese (weight 72.1 kg; height 6’1”,
body-mass index 21), non-diabetic, and had been on a daily
dose of 2-8mg of dexamethasone intermittently (equivalent to
prednisone 25-50mg daily) for approximately a year and half
for GBM.
On admission, the patient was in no acute distress and denied
abrupt or sharp onset of thoracic or abdominal pain. Physical

Figure 1. CXR: Apparent widening of the superior mediastinum.
Mild atelectasis in the left midlung is noted.

exam revealed a well healed scalp scar from previous GBM
resection, expressive aphasia, and chronic right sided weakness.
Despite chronic steroid use, there were no physical manifestations of Cushing’s syndrome such as round face, fat pad, or
purple stria. He had equal blood pressures in both arms and
intact pulses bilaterally. The patient’s fasting glucose was within
normal limits.
A plain chest radiograph demonstrated widening of the
mediastinum, which was new compared to a study 6 months
earlier (Figure 1). A follow up chest CT with contrast showed
anterior-superior mediastinum lipomatosis (Figure 2). The
pericardium and other surrounding structures were not
involved. Mediastinum and hila were within normal limits
on chest CT performed 7 months prior. The diagnosis of ML
was made by CT. Since the patient remained asymptomatic,
no further workup was required. Although steroids have been
associated with ML, Neuro-Oncology deemed the benefits
of steroids outweighed the risks. Therefore, the patient
continued steroid treatment and was discharged home with
Neuro-Oncology follow up.

Discussion
Mediastinal Lipomatosis is a benign cause of mediastinal
widening secondary to mature adipose deposition. Although
our patient remained asymptomatic with ML, symptoms

Figure 2. CT scan with contrast: Anterior-superior mediastinum
lipomatosis.
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may include dyspnea, cough, and chest pain.3-5 Physical exam
findings range from a benign exam to decreased breath sounds,
obesity, or associated signs of Cushing’s syndrome. 3,4 Unlike
most case reports reviewed, our patient did not have physical
exam signs of obesity or steroid excess. The patient, however,
was on chronic steroids, which may be associated with ML.3,4
Though the time course is unknown for development of fat
accumulation, this patient appears to have developed ML within
6-7 months.
In most case reports, ML is identified by an incidental
mediastinal widening on chest radiographs. Although ML is
considered benign, it does have certain clinical implications.
Kashikar et al report a patient presenting with progressive
shortness of breath who was ultimately found to have segmental
atelectasis of the lung related to ML.1 In the case presented by
Peek et al, ML caused right hemidiaphragm paralysis secondary
to phrenic nerve compression and mimicked cardiomegaly on
CXR.6 ML can also cause low voltages on electrocardiograms.2
A rare complication of ML is superior vena cava compression,
which can cause difficulty with central venous catheterization.7
In one case, a primary mediastinal large B-cell lymphoma was
found within mediastinal lipomatosis.8 A more significant
complication is laryngeal compression secondary to excess
adipose tissue in the mediastinum leading to airway compromise
and right ventricular outflow tract obstruction.9-10

Treatment
Treatment of ML depends on the degree to which it affects
the patient. ML is usually asymptomatic and no treatment is
necessary. Often, the patient is obese, and weight loss is strongly
recommended.2,16 Tapering steroids may improve symptoms and
reverse radiological findings.5 In the case presented by Nguyen
et al, surgical resection was required to relieve symptoms of
dyspnea caused by ML.4

Differential
ML is an uncommon cause of mediastinal widening and
acute causes must be excluded first. Emergencies include
aortic dissection, esophageal rupture, trauma, hemorrhage
or mediastinitis. 12 Mediastinal widening on CXR can be
followed up with immediate CT, MRI and Echocardiogram.
Critical warning signs can be elicited on history and physical
exam. Notably, aortic dissection often manifests as sudden
onset of sharp, tearing ripping pain in the chest or back with
maximal intensity at onset leading to absent pulses, >20
BP mmHg difference in blood pressure between arms, and
possible neurological abnormalities.11, 12 Other critical causes of
mediastinal widening include anterior mediastinal masses such
as lymphoma and thymoma, which can be distinguished from
benign lipomatosis by imaging.13, 14

Imaging
The study of choice for diagnosis of ML is CT or, less often, MRI.
Initial CXR will show a widened mediastinum with increased
lucency. A follow up CT reveals a collection consistent with fat
(attenuation of 50 to 100 Hounsfield units). The adipose tissue
can extend from the superior mediastinum to the diaphragm
and may involve the heart and lungs. Interestingly, CT may
also show incidental heart involvement with a characteristic
dumbbell shape within the interatrial septum. However, of those
studied with interatrial septum lipomatosis, no patient had
evidence of electrocardiogram or other cardiac abnormalities,
again emphasizing the benign nature of this diagnosis.13-15

Conclusion
In contrast to medical emergencies and malignancy, mediastinal
lipomatosis is a rare but benign cause of mediastinal widening
on CXR. Symptoms caused by mediastinal lipomatosis
include dyspnea, cough and arrhythmias, but most people
are asymptomatic. The diagnosis is made by CT once acute
conditions have been ruled out. Since the prevalence of obesity
and use of steroids is increasing, it is important to understand
the presentation, diagnosis, and treatment of mediastinal
lipomatosis as we will likely see more cases of ML in the future.
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Metastatic Lip Cancer of Unknown Primary
Jonathan Dunn, MD, Jerry Hsieh, MD

Background
As housestaff, we seldom have the chance to admit a patient
with cancer of unknown primary. Even if a patient presents
with metastatic cancer, it is frequently evident what the primary
cancer is based on epidemiology and imaging. However, in this
case we have the unique opportunity of describing a metastatic
cancer that presented as a lip carcinoma with several possible
primary sources. Our goal is to guide the reader through
the thought process involved with determining the primary
malignancy in patients presenting with metastatic disease.

Case Presentation
A 54-year-old female with a 30-pack-year smoking history
presented to the emergency department with pain and swelling
of the right lower lip. The symptoms started one month ago
with mild to moderate pain, and progressed within one week to
significant swelling. She had developed a lip abscess two weeks
prior that was incised and drained, but now presented with
worsening drainage, swelling, and pain. She also had fevers and
a non-productive cough for one month.

Investigation
On admission to the hospital, the patient was afebrile and had
normal vital signs. Her right lower lip was noted to be indurated,
with no fluctuance. There was no area of warmth or erythema
surrounding the area of induration. Admission labs were
within normal limits. Initial chest x-ray revealed consolidation
within the right middle lobe and right lower lobe, as well as a
moderate right pleural effusion. Maxillofacial CT with contrast
revealed an organized rim-enhancing fluid collection within
the soft tissues overlying the right mandible with overlying
skin ulceration and surrounding inflammatory changes in the
adjacent subcutaneous tissues.

Hospital Course
The initial differential diagnosis of the patient’s lip lesion
included abscess, cellulitis, and malignancy. On admission, she
was empirically treated for cellulitis and community acquired
pneumonia. On hospital day 2 she was taken for a lip biopsy,
which revealed ulcerated lesions with clusters of markedly
atypical cells, most consistent with an ulcerated squamous cell
carcinoma (SQCC). Immunohistochemistry stains showed that
the tumor cells were positive for cytokeratin CK7 and negative
for CK20, TTF1/Napsin, CK5/6 and mucicarmine. These were
not consistent with a cutaneous SQCC as will be discussed

Figure 1. CXR: Apparent widening of the superior
mediastinum. Mild atelectasis in the left midlung is noted.
later on. These results necessitated a metastatic workup to
determine the primary source. A CT of the chest was obtained
which showed a large right hilar mass, a new spiculated 7mm
nodule in the inferior left lower lobe, and new mediastinal and
hilar adenopathy. It also showed a large hypodense lesion with
irregular margins within the right hepatic lobe. Based on these
findings, a fine needle aspiration of the lung was obtained. The
immunohistochemistry of the lesion matched that of the lip.
These findings favored a diagnosis of primary lung cancer with
metastasis to the lip, but could also represent either unknown
primary or synchronous malignancies. Primary squamous cell
carcinoma of the lip was deemed unlikely since these cancers
are most often CK7 negative. Based on these findings, the
decision was made by the primary oncologist to go forward
with treatment of primary lung cancer, and platinum based
chemotherapy was initiated.

Discussion
In the initial approach to a cancer of unknown primary, an
evaluation of immunohistochemical markers can help narrow
the list of possible cancers. The first step is often to stain for
cytokeratins, specifically CK7 and CK20. The patient tested
positive for CK7, and negative for CK20, which could indicate
any of the following cancers: non-small cell lung, small cell lung,
breast, endometrial, nonmucinous ovarian, mesothelioma,
and squamous cervical carcinoma.1 In general, CK7+/CK20strongly favors lung carcinoma.2 After a metastatic workup with
imaging that yielded a lung and liver nodule, it was thought that
the lip lesion was most metastatic from the lung.
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Further analysis of the lesion involved lung cancer specific
markers. Napsin and TTF1 are markers for lung adenocarcinoma (ADC) and both used in conjunction have 74%
sensitivity and 87% specificity for ADC. 3 These were both
negative indicating a low likelihood of lung ADC. Additionally,
p63 and CK5/6 markers were analyzed, which are used for
distinguishing SQCC from ADC of the lung. ADC does not
express either marker, whereas SQCC has approximately 75%
chance of positive expressivity. Virtually all ADC and SQCC
will not express CK20.4
Metastatic carcinomas tend to be poorly differentiated, as is
the case with this patient. Unfortunately, the immunohistochemistry of this particular carcinoma does not strongly favor
ADC or SQCC; however, the histology more closely resembles
poorly differentiated SQCC. At this time, the diagnosis favors a
lung SQCC metastatic to the skin of the face.

“A Mayan Wonder – Chichen Itza”
photograph by Rina R. Shah
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Key Points
A thorough pathological examination is important in the
diagnosis and treatment of tumors of unknown primary.
Important components of this examination include cytokeratin
markers CK7 and CK20, as well as other markers such as TTF1,
Napsin, CD5/6 and mucicarmine. Further analysis depends
largely on the clinical picture. For our patient, a closer look at
her long smoking history along with the information gathered
from cytopathology favored a diagnosis of lung cancer, and
appropriate treatment was given.
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Sudden Onset Blindness in a Patient with Mixed
Connective Tissue Disease
Chris Terry, MSIII, Prachi Thanawala, MD, Erika Villanueva, MD

Case Presentation
A 66-year-old Caucasian female recently diagnosed with mixed
connective tissue disease presented with acute onset vision loss
in the left eye. The patient first noted a “hazy-shower” that
caused blurry vision with loss of peripheral vision. Her vision
progressively worsened over a four-day period, resulting in
complete blindness in the left eye and the onset of blurry vision
in her right eye. She denied any eye pain, discharge, photophobia
or similar symptoms in the past. The patient did note a very
mild headache for four days but denied any other symptoms.

Investigations
The patient was admitted for workup of left eye vision loss.
Rheumatology was consulted for concern of autoimmune
vasculitis, and the patient was started on IV methylprednisolone
(1g daily). There was a concern for giant cell arteritis (GCA).
Therefore bilateral temporal artery biopsies were obtained.
The biopsy specimens showed no signs of GCA; however some
ophthalmic artery occlusion was noted. There was concern for
further thromboses, so MRI, MRA, and MRV of the head, CT
of the chest, abdomen and pelvis, ultrasound of the carotid
arteries, and trans-esophageal echocardiogram were performed.
However, all of these imaging studies were non-diagnostic.
The patient had an Orbital Duplex Scan that showed
significantly reduced blood flow to both eyes. Laboratory
testing for autoimmune markers were significant for a positive
rheumatoid factor (RF) and positive anti-cyclic citrullinated
protein (anti-CCP) antibody (Ab). An ANA screen was positive
with a titer of 1:80. Anti-ssDNA and anti-dsDNA antibodies
were both moderately elevated. All other studies were
non-diagnostic including anti-Smith Ab, RNP Ab, anti-SS-A
Ab, anti-SS-B Ab, C-reactive protein, erythrocyte sedimentation
rate, cryoglobulins, C-ANCA, P-ANCA.

Differential Diagnosis
Vasculitides are defined by the presence of inflammatory
leukocytes in vessel walls with reactive damage to mural
structures and may occur as a primary process or secondary to
another underlying disease.1 There was initial concern for GCA
due to the age of onset, presence of headaches, and absence of
other symptoms. However, the bilateral temporal artery biopsies
were negative. Essential cryoglobulinemic vasculitis was also
considered; however it was ruled out based on the absence of
serum cryoglobulins.
Given the patient’s past medical history and positive ANA,
the medical team suspected an underlying connective tissue

disorder. Additionally, due to the absence of serum ANCAs,
the differential diagnosis was narrowed to a non-ANCA
vasculitides. An important differential to bear in mind is
systemic lupus erythematosus (SLE), a chronic, autoimmune
connective tissue disorder affecting multiple organ systems
often with a relapsing and remitting clinical course. Ocular
manifestations, occurring in up to one third of patients, result
from localized ischemia.2,3 Lupus retinopathy is one of the most
common vision-threatening complications of SLE, occurring in
up to 29% of patients.6-8
Another etiology to consider is rheumatoid arthritis (RA). Blood
vessel inflammation is a central feature of RA.9 The mean onset
of vasculitic symptoms is 13.6 years after the initial diagnosis
of RA, and patients typically have developed rheumatoid
nodules. 10,11 The two principal ocular manifestations of
rheumatoid vasculitis are episcleritis and peripheral ulcerative
keratitis.12,13 The presence of an elevated RF and positive ANA,
as well as a past medical history of nodular episcleritis, led to a
high clinical suspicion for rheumatoid vasculitis.

Treatment
Rheumatology and Ophthalmology agreed to continue the IV
methylprednisolone. On hospital day four, the patient was given
cyclophosphamide (750 mg/m2) to be dosed monthly. This
decision was based primarily on two critical studies investigating
the efficacy and safety of pulse IV cyclophosphamide.
In mildly progressive ocular inflammation, therapy is often
initiated with immunomodulatory agents prior to pulse IV
cyclophosphamide. However, with failed immunomodulatory
therapy or rapidly progressing inflammation at presentation,
initiation of pulse IV cyclophosphamide is warranted. In 2004,
Durrani et al. demonstrated the control of inflammation and
steroid-sparing effect of pulse IV cyclophosphamide in 38
patients with severe ocular inflammation of diverse etiologies.14
Cyclophosphamide is a non-specific alkylating agent that exerts
a cytotoxic effect on rapidly proliferating cells. It has shown
remarkable safety in the rheumatologic and dermatologic
literature when used IV for limited periods.15,16

Outcome and Follow-up
The patient continued on methylprednisolone (1g daily) for
a total of eight days. On hospital day nine, her daily dose of
methylprednisolone was decreased to 250 mg. At this time,
her vision was stable in the right eye; however she still had
complete loss of vision and light perception in her left eye. On
hospital day ten, her steroid dose was adjusted to prednisone
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(100 mg daily), which she would continue until her next dose
of cyclophosphamide. The patient had a repeat Orbital Duplex
scan on hospital day ten which showed stable parameters in
the central retinal artery of the right eye and improved flow in
the temporal vessel of the short posterior ciliary system in the
left eye. On hospital day 11, the patient was medically stable
for discharge with close follow up with Ophthalmology, Retina
Clinic, and Rheumatology.
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A 19 Year Old Male With HIV Presents With Diffuse
Lymphadenopathy
Brian Curtis, MD, Subhashini Sellers, MD, Jay Sellers, MD, Jack Bruminhent, MD

Background
In 1872, Moritz Kaposi first described “an idiopathic multiple
pigmented sarcoma of the skin,” now identified as Kaposi’s
sarcoma (KS).1 While multiple forms of KS exist, over 95% of the
cases diagnosed in the US since 1981 are of the AIDS associated
variety.2 Kaposi originally described KS as skin lesions that can
progress to visceral involvement. However, in a small number
of cases, KS can appear in the viscera without skin involvement.
These alternate presentations of KS are difficult to diagnose;
therefore, it is critical to recognize them when considering
differential diagnoses, particularly in patients with HIV.

Case Presentation
An 18-year-old African American male with a history of HIV
presented with progressive worsening of diffuse and painful
lymphadenopathy fore five weeks prior to admission. The
patient was diagnosed with HIV in 2010 and due to insurance
issues, was never treated with highly active antiretroviral therapy
(HAART). His last CD4 count (approximately two weeks prior
to admission) was 411 and he had no history of opportunistic
infections. He first noticed swelling in his neck, under his
armpits and in his groin five weeks prior, which had become
progressively more painful. The patient denied fevers, chills or
weight loss, but did report significant night sweats and episodes
of hemoptysis with clots. He denied shortness of breath or chest
pain. He also denied recent travel, history of incarceration,
homelessness or exposure to active tuberculosis infection.

Figure 1. CT of the chest with IV contrast demonstrates ground
glass opacity in the right upper lobe and bulky enhancing
adenopathy in the bilateral axilla.

On admission, the patient’s physical exam revealed numerous
palpable, mobile and tender lymph nodes in the cervical,
axillary and inguinal regions bilaterally. There was no overlying
erythema and no skin lesions noted elsewhere. His lungs were
clear to auscultation bilaterally. The remainder of his physical
exam was within normal limits. His labs upon admission were
notable for a hemoglobin of 9.4 and a platelet count of 9,000.
The remainder of his labs were within normal limits. A chest
x-ray demonstrated no consolidation or infiltrates.

Hospital Course
The differential diagnosis for the HIV patient presenting with
diffuse lymphadenopathy includes lymphoma, mycobacterium
avium intracellular infection, tuberculosis with extrapulmonary involvement, fungal infection, Castleman’s disease,
Kaposi’s Sarcoma, leukemia, infectious mononucleosis
secondary to EBV or CMV, Bartonella infection (cat scratch
disease), toxoplasmosis and secondary syphilis. Malignancy
is a significant concern with the co-existing anemia and
thrombocytopenia. He underwent a CT of the chest (Figure 1),
abdomen and pelvis (Figures 2 and 3). Given his complaints of
hemoptysis, the patient was placed on respiratory isolation and
TB was ruled out by sputum acid fast bacilli stain and culture.

Figure 2. CT of the abdomen with IV contrast shows bulky
enhancing intra- abdominal and para-aortic lymph nodes.
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for which he was treated with IVIG and started on HAART.
He was started on romiplostim to stimulate platelet production.
On day 4 of his admission, the patient underwent a left inguinal
lymph node excisional biopsy. Pathology was consistent
with KS (Figures 4-7). It was assumed that his hemoptysis
represented pulmonary involvement, although this could not
be confirmed by bronchoscopy in the setting of thrombocytopenia. Although first line treatment for HIV-associated KS
is HAART, the patient’s extensive and symptomatic disease
required additional therapy. He received radiation for his bulky
cervical adenopathy; however, he developed stridor during
treatment and was intubated for airway maintenance. His ICU
course was complicated by ventilator acquired pneumonia and
he required a tracheostomy for continued airway maintenance.
He was eventually weaned from the ventilator and started on
liposomal doxorubicin on the general floor. After a nearly two
month hospitalization, he was deemed stable for discharge
home with a plan to continue HAART, weekly romiplostim,
and chemotherapy as an outpatient.
Figure 3. CT of the abdomen and pelvis demonstrates bilateral
bulky enhancing inguinal lymph nodes.

The patient was seen for follow up three weeks after discharge.
His hemoptysis had resolved and his lymphadenopathy had
decreased in size and was less painful. He continued to receive
doxorubicin every other week and he required romiplostim
for persistent thrombocytopenia. He no longer required
supplemental oxygen and ENT planned to decannulate his
tracheostomy.

Discussion
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Figure 4. Low power H&E stain of excised left inguinal lymph
node demonstrates distortion of the normal lymph node
architecture.

The Hungarian dermatologist Moritz Kaposi first described
classic KS in 1872, as a rare, slow growing cutaneous tumor
that mainly affects 50 to 70-year-old Jewish Mediterranean and
Eastern European males. Since then, other varieties have been
described including the African or endemic, and the immunosuppressed forms.3 In 1981, a fulminant and disseminated form
of the disease appeared alongside HIV/AIDS. In fact, early in
the epidemic, 48% of AIDS patients in the US presented with
KS.2 KS typically begins with cutaneous lesions, which are
usually dark patches, papules, plaques or nodules. Diagnosis
requires biopsy with histopathology illustrating a multicentric
angioproliferative spindle cell tumor that stains positive for the
endothelial markers CD31 and CD34. Positive stain for HHV-8
is also necessary but not sufficient for diagnosis, as the virus
is also associated with multicentric Castlemans disease and
primary effusion lymphoma in HIV patients.

Rapid plasma reagin and monospot tests were also negative and
repeat CD4 count was 194. The history, laboratory results and
radiological findings required excisional lymph node biopsy for
definitive diagnosis, but this was limited by the patient’s severe
thrombocytopenia. Hematology was consulted and determined
the thrombocytopenia likely represented HIV associated ITP,

Although the vast majority of patients with KS present with skin
lesions, the disease can involve the viscera, most commonly the
oral mucosa, lung, liver, spleen, lymph nodes and the GI tract.
Patients in later stages of disease can also experience fevers,
weight loss and night sweats. Visceral involvement usually
progresses from cutaneous disease, but in a small number of
cases, it can be the primary site of involvement. This is seen
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Figure 5. High power H&E stain of excised
left inguinal lymph node with infiltration by
angioproliferative spindle cells

Figure 6. Low power CD34 positive
stain of excised left inguinal lymph node.
Positive stain for CD 34 indicates vascular
endothelium. Normal lymphatics do not
stain positive for CD34.

in KS cases involving the lymph nodes. Direct cutaneous
invasion into nodes does not appear to worsen prognosis, but
KS presenting solely with generalized lymphadenopathy is
recognized as a disease more common in children and young
adults that is associated with a worse prognosis.4
Regardless of the stage of KS, first line treatment is HAART.
This has been shown in several trials, including one in which
80% of patients naive to HAART with cutaneous disease showed
regression with HAART alone.5 The utility of HAART extends
to prevention as well, as demonstrated by the sharp decrease in
AIDS and KS incidence with anti-retroviral therapy introduction
in the 1990s. In fact, the incidence of KS decreased from 30/1000
patient-years prior to 1995 to 0.03/1000 patient-years in 2001.2
Other modalities of treatment include radiation therapy and
cytotoxic drugs. Radiation therapy for local disease can be an
excellent option, with some series reporting 68-90% resolution
of lesions, although the response in the epidemic form is
less durable than in other forms of KS.6,7 Patients with more
disseminated disease can be treated with systemic chemotherapy.
Liposomal doxorubicin has been reported to have significantly
higher response rates and possibly fewer side effects than other
regimens including doxorubincin, bleomycin and vincristine.8,9
Based on these studies, liposomal doxorubicin is now considered
first-line treatment for advanced KS. Paclitaxel has also shown
promising results and is considered second-line therapy.9

Conclusion
As KS is a heterogeneous disease, it must always be considered
in the workup of patients with HIV/AIDS. As demonstrated by
our case, patients can present with normal CD4 counts, lack

Figure 7. HHV8 positive nuclear stain of
excised left inguinal lymph node. Positive
HHV8 stain is necessary for the diagnosis of
Kaposi Sarcoma

skin lesions, and present with symptoms secondary to visceral
involvement, including adenopathy, hemoptysis, gastrointestinal bleeding, and systemic symptoms. While KS is rarely
a cause of death, it is not curable and can be disabling. Current
management options are often able to symptomatically alleviate
and improve quality of life.
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A Devastating Storm
Eve Merrill, MD

Case Report

Discussion

A 26-year-old female with no significant medical history
presented with palpitations and shortness of breath. Two weeks
prior, she experienced rhinorrhea and congestion.Vital signs
on admission were temperature 96.6°F, heart rate 252 beats
per minute, blood pressure 127/74 mmHg, respiratory rate 24
breaths per minute, oxygen saturation 98% on room air. On
exam, the patient was tachycardic and had a large, homogenous
thyroid without any palpable nodules. The rest of her physical
exam was unremarkable.

Thyroid storm is a state of severe hyperthyroid crisis (thyrotoxicosis) that causes organ dysfunction. Excess thyroid hormone
produces a massive sympathetic (adrenergic) response and
can damage the heart, liver, lungs, and central nervous system.
Interestingly, the severity of thyroid dysfunction in thyroid
storm does not correlate with thyroid levels. Thus, one cannot
use thyroid levels alone to distinguish between hyperthyroidism
and thyroid storm. Instead, there is scoring system developed
by Burch and Wartofsky in 1993 to help establish a diagnosis
of thyroid storm. Diagnostic criteria includes a point scale
for varying degrees of cardiovascular dysfunction (including
tachycardia and atrial fibrillation), heart failure, thermoregulatory dysfunction, central nervous system dysfunction, gastrointestinal-hepatic dysfunction, and a precipitant history event.
A score below 25 makes thyroid storm unlikely, while scores
between twenty-five and forty-four supports the diagnosis and
a score of 45 of more is highly suggestive. Our patient had a
score of 85.

Laboratory data revealed total bilirubin 4.4 mg/dL, aspartate
aminotransferase 245 units/L, alanine aminotransferase 263
units/L, thyroid stimulating hormone (TSH) 0.02 mIU/L, free
thyroxine (T4) 5.5 ng/dL, and free triiodothyronine (T3) 21.4 pg/
mL. Electrocardiogram revealed supraventricular tachycardia.
Computed tomography angiogram of the chest revealed a
grossly enlarged thyroid, a left lower lobe infiltrate, and no
evidence of pulmonary embolism. The patient was cardioverted
to sinus rhythm and was started on a continuous infusion of
diltiazem. She then became hypotensive and tachypneic and was
subsequently intubated. Thionamide medications, including
methimazole and propylthiouracil, for the patient’s hyperthyroid
state were initially held due to acute liver failure.
On the second day of admission, the patient developed rapid
atrial fibrillation and was started on an esmolol infusion. Shortly
thereafter, she became bradycardic and had a cardiac arrest
with successful resuscitation. She then had a transvenous pacer
placed as her asystolic event was attributed to a long conversion
pause. Echocardiogram showed an ejection fraction of 10% with
severe global systolic dysfunction, likely representing a stressinduced cardiomyopathy compounded by ischemia from the
cardiac arrest.
In light of her rising liver function tests (transaminitis greater
than 1000 units/L), the patient was started on methimazole,
potassium iodine, and high-dose hydrocortisone for her
severe hyperthyroid state. Ultrasound revealed an enlarged,
heterogeneous thyroid with increased vascularity and serum
studies showed anti-TSH receptor antibodies. Once her thyroid
levels and liver function improved, propylthiouracil was used
instead of methimazole. The patient also developed acute
kidney injury requiring continuous venovenous hemodialysis.
As she continued to clinically deteriorate, she was started on
Extracorporeal Membrane Oxygenation (ECMO). The plan was
to ultimately have the patient undergo a thyroidectomy once she
became hemodynamically stable. Unfortunately, the patient had
uncontrollable bleeding from her ECMO graft site and passed
away on hospital day six.

24

Thyroid storm usually develops after an inciting factor in a
patient with undertreated or undiagnosed hyperthyroidism.
Precipitating stressors include infection, surgery, trauma, and
a cardiovascular event. Other possible triggers include discontinuation of hyperthyroid medications or exposure to iodine,
including intravenous contrast or amiodarone. The underlying
hyperthyroid state is most commonly due to Graves’ disease,
but other causes of hyperthyroidism include toxic adenoma,
toxic multinodular goiter and Hashimoto’s thyrotoxicosis. Our
patient likely had undiagnosed Graves’ disease and an upper
respiratory tract illness as her inciting event.
Medical treatment of thyroid storm aims to stop thyroid
hormone production within the gland, inhibit the release
of thyroid hormone, and inhibit conversion of T4 to T3. In
addition, supportive treatment for adrenergic symptoms and
management of end organ dysfunction are crucial. Mainstays of
treatment include beta-blockers, thionamide (propylthiouracil
or methimazole), iodine, steroids and for definitive therapy,
thyroidectomy. Propranolol is the first line beta-blocker
because it provides anti-adrenergic effects and also inhibits
the peripheral conversion of T4 to T3. Propylthiouracil is the
thionamide of choice in severe, life-threatening thyroid storm
as it blocks peripheral conversion of T4 to T3. Methimazole is
recommended for severe non-life threatening thyroid storm as it
has a longer half-life than propylthiouracil, normalizes T3 more
rapidly, and has less hepatotoxicity. Despite our patient’s critical
hyperthyroid state, she was initially started on methimazole
because of her severe liver failure. She was transitioned to
propylthiouracil once her thyroid hormone levels improved and
her liver function stabilized. Mortality associated with thyroid
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storm is predicted to be twenty to thirty percent, making it
crucial to diagnose early.
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Palpable Purpura in a Vietnamese Teenage Girl
Akram Mustafa, MD, Edward Len, MD, Alan Chiu, MSIII

A 19-year-old Vietnamese female with no significant past
medical history presented to the emergency department (ED)
with fevers, sore throat, generalized myalgias, arthralgias,
and a worsening lower extremity rash for the past two weeks.
Approximately one week after the onset of constitutional
symptoms, the patient noticed a rash developing on the anterior
surface of her legs. Three days prior to hospitalization, her
primary care physician prescribed cephalexin for her, but she
didn’t recall what it was for. When her symptoms continued
to worsen the next few days, she presented to the ED. In the
ED, she also complained of abdominal tenderness. She had no
previous hospitalizations, and her vaccinations were up to date.
She also had a small tattoo noted on her neck that she reported
receiving at a reputable place four years ago. She was sexually
active with her boyfriend, and did not regularly use condoms.
However, she denied any genitourinary symptoms.
Upon presentation, the patient had a fever and mild tachycardia.
However, she was in no acute distress. Physical examination
revealed diffuse palpable petechiae along the anterior part of both
lower legs. The patient also had a developing rash over the anterior
arms bilaterally. The rash spared her palms and soles. Abdominal
exam revealed right upper quadrant (RUQ) tenderness with mild
hepatomegaly. The rest of the exam was normal. On labs, patient
was found to have a microcytic anemia, normal white blood
cell and platelet count. Urinalysis revealed mild proteinuria and
hematuria. However, the patient had normal renal function.
Ultrasound of the kidneys revealed normal-appearing kidneys.
Further work-up revealed mildly elevated ALT (98), AST (76),
INR (1.86), and ESR (55). With the liver abnormalities, a RUQ
ultrasound was also done, which revealed mild hepatomegaly
but was otherwise normal. Screens for possible viral (including
viral hepatitis, Monospot), bacterial (anti-streptolysin O titers,
cultures), and autoimmune (antinuclear antibody, C-reactive
protein) causes were all normal.
The clinical picture of palpable purpura, oligoarthralgia,
abdominal pain and renal involvement as demonstrated by
the microscopic hematuria, and further evaluations from
Rheumatology, Infectious Disease, and Nephrology led to
Henoch-Schonlein purpura (HSP) as the most likely diagnosis
in this patient. The exact etiology of the HSP in this patient
however was unknown. The most likely triggers were either a
previous viral infection or medication-induced.
Skin biopsy was not obtained because the clinical picture was
deemed enough to diagnose HSP. The patient demonstrated gradual
improvement with supportive care and no further work-up was
necessary. The elevated liver enzymes and INR also normalized.
Despite the patient’s proteinuria, her renal function was normal
so a renal biopsy was deemed unwarranted. On hospital day four,
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Figure 1. Palpable Purpura
the patient was discharged with instructions to follow up with her
primary care physician for any recurring symptoms.

Discussion
Henoch-Schonlein purpura (HSP) is a small-vessel vasculitis
characterized by palpable purpura (without thrombocytopenia),
abdominal pain, and arthritis. It is a syndrome predominantly
seen in children; the highest occurrence of HSP is in patients
between the ages of 3 and 5. Ninety percent of HSP cases are
in children under the age of ten.1 However, HSP can be seen at
any age, though the occurrence in adults is rare and reported in
3.4 -14.3 cases per million.3
The precise etiology of HSP is unknown. The proposed triggers
are generally infectious; an upper respiratory infection often
precedes HSP symptoms in 90% of cases.2 Other proposed
infectious agents include group A Streptococcus, MRSA, H.
pylori, Parvovirus B 19, Hepatitis B, HIV, Stenotrophomonas
maltophilia.3 In adults, a wider variety of antigenic stimuli
have also been suggested to predispose to HSP: vaccinations,
insect bites, food allergies and drugs. Medication-induced
HSP is particularly more common in adults and has been
seen in association with ACE-inhibitors, ARBs, NSAIDs, and
antibiotics.2
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Whatever the antigenic stimuli may be, the cross reactivity
between the offending agent and small vessel endothelial cells
leads to a leukocytoclastic vasculitis. Immunoglobulin A (IgA)
has been found to be the key mediator of this reaction.2 Immune
complexes and chemotactic factors activate polymorphonuclear
leukocytes causing inflammation and eventually necrosis of
vessel walls. IgA complex depositions accumulate primarily in
the skin, intestinal mucosa, joints and kidneys–precisely the
organ systems behind the classic clinical features of HSP.3
The main clinical features seen with HSP are palpable purpura,
abdominal pain, arthritis, and renal insufficiency. A retrospective
analysis of 250 adult patients with HSP reported a purpuric rash
in 96% of cases, arthritis in 61%, gastrointestinal disease in
47%, and renal disease in 32%.3 The classic skin lesions of HSP
start as multiple small, painless, erythematous macular lesions
that combine into palpable purpura. The rash is symmetrical
and more prominent in dependent areas of the body such as
the lower extremities. The arthritis/arthralgia seen in HSP is
migratory and oligoarticular. The arthritis is non-deforming
and the joints are not usually swollen or tender. Gastrointestinal
involvement often presents as colicky pain with or without
bleeding from the large or small bowel. A potentially severe
complication is intussusception. Renal disease is considered the
most serious manifestation of HSP, its involvement can range
from microscopic hematuria to fulminant nephrotic syndrome.
The diagnosis of HSP is clinical. The European League Against
Rheumatism and Pediatric Rheumatology European Society
criteria include one mandatory criterion and at least one of four
minor criteria. The mandatory criterion is palpable purpura
predominantly in the lower limbs. In addition, there must be
one of the following: diffuse abdominal pain, IgA deposition
in any tissue biopsy, arthritis/arthralgia, or renal involvement.
Urinalyses are often abnormal and may reveal anything
from microsopic hematuria to nephrotic range proteinuria.
Inflammatory markers (C-reactive protein, erythrocyte

sedimentation rate) are typically elevated. The diagnosis can
be supported by a tissue biopsy that shows vasculitis with
IgA immunofluorescence. 2,3 There will also be perivascular
infiltration of neutrophils.2 In cases of uncertain diagnosis or
severe renal disease a renal biopsy may be performed.
Treatment is symptom-directed. NSAIDs are used in mild cases
for joint pain. Colchicine can be used in cases of severe skin
lesions. In pediatric HSP, no guidelines exist for the management
of GI and renal involvement of the disease, and far fewer
recommendations exist for adults. Glucocorticoids have been
used to treat GI symptoms successfully, as they have been proven
to shorten the duration of these symptoms. Corticosteroids can
also be used in patients with renal involvement, and in severe
disease can decrease proteinuria significantly.2 It should be
noted, however, that there is little evidence to support the use
of glucocorticoids to prevent renal disease once the diagnosis
of HSP is established. 6 Leukopheresis, cytotoxic agents and
immunoglobulin have been used in refractory cases.2,3
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Paraneoplastic Acral Vascular Syndrome
Daniel M. Kopolovich, MSIII, Dean D. Laganosky, MSIII, Allison A. Greco, MSIV,
Emma Weaver, MD, Rahul Malhotra, MD, Phoebe Holmes, MD, John Stewart, MD

Introduction
Cases of rheumatologic phenomena coinciding with malignancy
have been well-documented in the medical literature. These
syndromes may be associated with common autoimmune
markers, potentially masking the underlying diagnosis of
malignancy. The association between malignancy and its
coinciding rheumatologic manifestations is poorly understood.
These paraneoplastic symptoms are more prevalent in
high-stage adenocarcinomas of the lung, breast, and ovary.
Possible mechanisms may include cytokine derangements,
blood hyperviscosity, and circulatory disruption. While some
evidence suggests that control of the primary tumor alleviates its
associated paraneoplastic symptoms, other proposed therapies
include heparin, prednisone, aspirin, and vasodilatory agents.
Efficacy is limited due to association of these syndromes with
high-grade malignancy. We describe the case of a patient
presenting with paraneoplastic acral vascular syndrome (PAVS)
in association with primary ovarian carcimona.1,2

Case
The patient is a 57-year-old female with a history of Hashimoto’s
thyroiditis and migraines, who presents with an ulcerating rash
of the fingertips and a tender discoloration of the plantar aspect
of both feet. The rash began four weeks prior to presentation
as a purple discoloration of the fingertips, progressing to a
desquamating, palmar rash with distal phalangeal ulceration
and necrosis of the fingertips. Almost simultaneously, the
patient experienced purple discoloration of the soles of her feet
bilaterally and described a sensation of “standing on marbles.”
She denies similar episodes in the past as well as sick contacts.
She reports experiencing excessive stress in preparing for her
daughter’s wedding, exposure to a new type of dryer sheet, and
a recent manicure/pedicure. The patient was recently treated
with two medrol dose packs, minocycline, nitroglycerin paste
(which had to be discontinued due to hypotension), and aspirin.
Following treatment, the patient had no relief of symptoms.
Review of systems was remarkable for bilateral knee pain, painful
mouth ulcers, a non-tender, erythematous scaling rash on the
elbows, back, and right thigh. She denied fever, weight loss,
fatigue, night sweats, change in appetite, or abdominal swelling.
She reported allergies to DEET (rash and trouble breathing)
and Demerol. Recent skin testing suggested sensitivity to wheat,
corn, and soy. Family history was significant for a mother with
giant cell arteritis, father who passed away from melanoma and
a sister with breast cancer. The patient also had two daughters,
one with Raynaud’s syndrome and celiac disease, and another
with Sjogren’s syndrome. The patient was a middle school math
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teacher and had no occupational exposures. Social history was
unremarkable.

Physical Exam
Physical exam revealed unremarkable vital signs. The patient’s
right hand was notable for purple discoloration of the distal 2nd
through 5th digits and necrotic ulcerations of the distal 2nd and
3rd digits (Figure 1). The left hand had purple discoloration
of the distal 1st through 5th digits. Both hands had slight
peeling of the palmar surface, not extending past the wrist.
There was mild swelling of the metacarpal-phalangeal joints
as well as proximal inter-phalangeal joints bilaterally. Purple
discoloration of the anterior plantar surfaces of bilateral feet was
also noted. Neurologic exam was intact. Patient had 2+ radial,
posterior tibial and dorsalis pedis pulses bilaterally, and no leg
edema. Faint crackles were auscultated posteriorly in bilateral
lower lobes of the lungs. No cervical, supraclavicular, axillary or
inguinal lymphadenopathy was palpated.
Lab values revealed the following: C-Reactive Proteins 10.9 (H),
Rheumatoid Factor: 16.9 (H), ANA (homogenous 1:160, speckled
1:160), Anti-Ro 8.0 (H), Anti-cardiolipin IgM 76 (H), Aldolase
11.7 (H). CA-125 118 (H) CA 15.3 (CA 27.29) 46 (H). Blood

Figure 1. Right Hand Rash
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count, coagulation profile, chemistry profile, liver function tests,
lipid profile and urinalysis were unremarkable. Additionally,
ESR, Anti-double stranded DNA, Anti Scl-70, c-ANCA,
p-ANCA, atypical p-ANCA, anti-MPO, Antiproteinase-3, Jo-1
antibody, Lyme panel, viral hepatitis panel, EBV/CMV PCR,
cold agglutinins, SPEP/UPEP, beta-2 glycoprotein, Celiac panel,
Lupus anticoagulant, RNP, CPK, heavy metals, CEA, and CA
19.9 were also normal. Chest radiograph showed a pulmonary
interstitial prominence with predilection for the lung bases.
CT chest/abdomen/pelvis showed patchy ground glass opacities
bilateral lower lobes, likely airspace filling process, of uncertain
significance. No interstitial lung disease. Diffuse retroperitoneal
adenopathy, extending from the diaphragm down through the
common iliac and external iliac territories and a cystic area in
the left adnexa. Another lymph node in the right supraclavicular
region was also seen and a fine needle biopsy of this node was
performed. Cytology was consistent with an adenocarcinoma of
ovarian origin. (Figures 2 & 3)
MRI of the abdomen and pelvis revealed a 5.0 cm solid and
cystic left adnexal mass, lesions of the left ileum consistent with
bony metastases, and extensive peritoneal carcinomatosis.

Figure 2. Diff quick stain of fine needle aspiration of lymph node
showing large malignant cells consistent with adenocarcinoma.

Discussion
This patient was diagnosed with paraneoplastic acral vascular
syndrome (PAVS) in association with primary ovarian
carcinoma. PAVS is an infrequently described phenomenon
characterized by acrocyanosis and subsequent necrosis of the
distal extremities secondary to malignancy. Most common
associations are adenocarcinoma of gastrointestinal and
pulmonary origin; however, ovarian cancer has been implicated
in a number of cases.1,3-5 Of these, the majority are found to be
metastatic at the time of diagnosis.5,6 In one literature review it
was shown that PAVS affects the hands in 94% of patients and
the feet in only 30%.1 The mean age of onset is 54.4 years old and
vasculitis precedes the diagnosis of malignancy by an interval of
1-38 months with a mean of 10 months.3,7

Figure 3. Wilms immunohistochemical stain of the cell block–the
stain is positive, confirming an ovarian origin, ruling out lung.

A number of authors have previously described atypical features
that may raise suspicion for an underlying neoplastic versus
primary rheumatologic pathology. Age greater than 50 years at
presentation, atypical involvement of the digits, as well as poor
response to steroids and vasodilating agents may indicate an
underlying malignancy. In contrast to primary rheumatologic
disorders, which occur more frequently in young women, these
conditions occur with equal frequency in men and women.1,2

consistent between patients. In one study, the pathology of the
digits showed leukocytoclastic small vessels, which was histologically different from the vascular involvement normally seen in
other diseases such as Rheumatoid arthritis, SLE, and Takayasu
vasculitis.7 Fibrinoid necrosis and intimal proliferation were also
noted.8 Other findings included disruption of the endothelium
and invasion of the vessels by neutrophils.7

Several proposed mechanisms for PAVS include: (i) ischemia
from tumor antigen immune complex deposition in the small
vessels of the digits, (ii) tumor infiltration into the cervical
plexus resulting in the release of vasoconstrictor substances,
(iii) direct endothelium invasion by the tumor cells, and (iv)
hypersensitivity reaction.4,7 However, these mechanisms are not

Treatment options for addressing the symptoms of PAVS include
steroids, IV prostacyclin, lower molecular weight Heparin,
aspirin, topical nitroglycerin, and calcium channel blockers.
More definitively, PAVS was found to resolve with cancer
treatment.1 In another study of 22 patients, clinical remission of
malignancy corresponded with the disappearance of PAVS.6 In
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summary, small vessel disease refractory to traditional therapies
warrants increased clinical suspicion for metastatic malignancy
so as not to delay definitive treatment.
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A 47-Year Old Female with Muscular Rigidity,
New-Onset Diabetes and Hypothyroidism
Michael A. Valentino, MD, PhD

Background
This case highlights a rare but devastating neurologic condition,
Stiff Person Syndrome (SPS). While symptoms of muscular
rigidity and spasms are associated with numerous neuromuscular
conditions, the association between SPS, autoimmune diabetes,
and other autoimmune disorders such as thyroiditis, pernicious
anemia, and vitiligo, could aid in the early diagnosis of this
debilitating condition.

Case Presentation
A 47-year-old African American female presented with six
months of progressively worsening rigidity and spasticity of her
axial muscles and extremities. The patient was in good health
until one and a half years prior to admission when she lost
consciousness while driving and was subsequently diagnosed
with epilepsy. Her daughter was a passenger in the car and
suffered a brief coma. Over the next year, the patient started
having anxiety with increasingly more frequent and severe
panic attacks. Six months prior to admission, she developed
muscle stiffness and painful spasms that were so severe, she
had difficulty ambulating and eventually became bed-bound.
Magnetic Resonance Imaging (MRI) of the brain and spine did
not reveal any pathology. Additionally, during the past year she

A

was diagnosed with diabetes, which was unusual given her thin
body habitus (Body-Mass Index of 20.9).

Investigations
The patient was admitted to the hospital for further work-up of
her neuromuscular symptoms. On physical exam, her abdomen
was tightly flexed and rigid, almost “board-like.” Musculoskeletal
exam revealed significant spinal lordosis with tight contraction
of the abdominal and paraspinal muscles. She also had several
muscle contractures including bilateral externally rotated and
adducted shoulders, bilateral elbow flexion, left wrist flexion,
bilateral knee extension, bilateral ankle plantar flexion, and
flexion of the left fingers (Figure 1a-b). There was no joint
effusion or erythema. Neurologic exam revealed cranial nerves
II-XII to be grossly intact. She had hypertonicity of the upper
and lower extremities, abdominal, and paraspinal muscles,
as well as intermittent myoclonic jerks of the limbs and neck
that could be elicited by auditory or tactile stimuli. She had
normal reflexes and no motor, sensory or cognitive deficits.
In addition, telemetry monitoring revealed wide fluctuations
in blood pressure (109/63 - 181/109 mmHg) and heart rate
(104-140 beats per minute). Admission labs were significant for
an elevated erythrocyte sedimentation rate, C-reactive protein
and thyroid stimulating hormone (Table 1).

B

Figure 1A, B. Representative X-rays showing upper extremity contractures
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Table 1. Pertinent lab values
Lab

Patient’s Lab Value

Reference Range

CRP

4.20

0.0-0.8 mg/dL

ESR

56

0-20 mm/hr

Hemoglobin A1C

6.3

<5.7%

TSH

7.06

0.3-5.0 mIU/mL

Free T4

1.0

0.7-1.7 ng/dL

Free T43

1.5

2.0-4.4 pg/mL

Vitamin B12

729

210-950 pg/mL

Negative

Negative

Anti-GAD65 Ab

>30.0

<1.0 units

Anti-Islet Cell Ab

1:64

<1:4

Anti-Amphiphysin Ab

0.1

<0.6 units

Anti-Thyroid Peroxidase (TPO) Ab

Anti-Thyroglobulin Ab

>1000

0.0-100.0 units

TSH Receptor Ab

<0.90

<1.75 units

Negative

Negative

Paraneoplastic Ab Panel (anti-Hu, anti-Ri, anti-Yo, cancer-associated
retinopathy (CAR) Ab, Lambert-Eaton myasthenic syndrome (LEMS) Ab)

Differential Diagnosis

Outcome & Follow-up

Neurology was consulted to evaluate the patient’s undiagnosed
neuromuscular disorder. The differential diagnosis included Stiff
Person Syndrome (SPS), neuromyotonia (Isaac’s syndrome), and
chronic inflammatory demyelinating polyneuropathy (CIDP).
However, there was also a suspicion of a psychological etiology
to her symptoms. She had blood tests sent for anti- glutamic
acid decarboxylase (GAD) 65, anti-voltage gated potassium
channel, and anti-GM1 ganglioside antibodies to evaluate for
SPS, neuromyotonia, and CIDP, respectively. Her anti-GAD65
antibody level was above the upper limit of detection. She was also
found to have markedly elevated anti-islet cell and anti-thyroid
peroxidase antibodies. Her elevated anti-GAD65 antibody level,
clinical presentation, and concurrent autoimmune diabetes and
thyroiditis led to the diagnosis of SPS. She was evaluated for the
paraneoplastic variant of SPS with anti-amphiphysin antibody,
a paraneoplastic antibody panel, and Computed Tomography
(CT) of the abdomen and pelvis, which were all negative.

Her hospital course was complicated by esophageal dysmotility
causing aspiration pneumonia, Pseudomonas bacteremia, and
ventilator-dependent respiratory failure. She was weaned from
the ventilator and discharged to rehabilitation with plans of
implanting a baclofen pump.

Treatment
She was started on a regimen of GABA-ergic and anti-spasticity
medications including high-dose diazepam, tizanidine,
baclofen, and dantrolene. She was then initiated on a five-day
course of intravenous immunoglobulin (IVIG) with no relief
in her symptoms. Joint manipulation under anesthesia was
unsuccessful. Botulinum toxin injections mildly improved her
range of motion.
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Discussion
Stiff person syndrome is a rare central nervous system (CNS)
disorder characterized by progressive rigidity of the axial
and proximal musculature with intermittent superimposed
spasms. The age of onset of SPS is typically the fifth decade,
and the disorder affects twice as many females as males.1 Two
symptoms are key to the characterization of SPS: (1) stiffness of
axial and proximal limb muscles due to continuous contraction
and co-contraction of agonist and antagonist muscles and (2)
superimposed intermittent painful spasms.2 In the classic form
of this disorder, patients will experience aching and tightness in
the neck and axial musculature and will develop hyperlordosis
due to simultaneous contraction of abdominal and paraspinal
muscles. The rigidity will spread to involve the proximal muscles
of the lower extremities and is often asymmetric at onset.3
Along with progressive stiffening of the musculature, patients
also experience intermittent, sudden painful spasms which
can be triggered by visual, auditory, or tactile stimuli, as well
as emotional stress.4 In some cases, individuals can identify
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a major stressful life event that preceded the onset of their
psychological and neuromuscular symptoms.5 The association
between the exacerbation of the patient’s symptoms and
emotional stress often leads to psychiatric evaluation. Early in
the course of the disease, a patient’s neuromuscular symptoms
may be non-specific, and the psychological features of anxiety
and depression may dominate the clinical picture. This often
leads to a diagnosis of a psychogenic movement disorder as
their neuromuscular symptoms progress. 5 Frequently, the
misdiagnosis of a psychogenic movement disorder can be
reinforced by the exacerbation of the patient’s symptoms by
emotional stress and the improvement of symptoms with
benzodiazepines. Finally, patients may suffer paroxysmal
autonomic dysfunction, dysphagia from esophageal dysmotility,
and seizures.6, 7
Case reports have demonstrated an association between SPS
and diabetes, but a major breakthrough in understanding the
pathophysiology of SPS came in 1988 when Solimena et al
identified antibodies against glutamic acid decarboxylase (GAD)
in the serum and cerebrospinal fluid (CSF) of a patient with SPS
and diabetes.8 GAD is the rate-limiting enzyme involved in the
synthesis of γ-aminobutyric acid (GABA), the major inhibitory
neurotransmitter in the CNS (Figure 2). The hypothesis that
the loss of GABA-signaling in the CNS is the cause of SPS
was supported by magnetic resonance spectroscopy showing
a selective reduction in GABA in the sensorimotor cortex of
patients with SPS.9

GAD
Glutamate

GABA

Figure 2.
Beyond anti-GAD antibodies, other autoantibodies targeting
GABA synthesis, transport, and signaling have been recognized
in patients with SPS (Table 2). More recently, antibodies
targeting GABAA receptor-associated protein (GABARAP),
have been identified in up to 70% of patients with SPS.11 A variant
of SPS that occurs as a paraneoplastic syndrome has also been
identified. This syndrome is most commonly associated with
breast cancer but also has been observed in colon, lung, thymus
cancers, as well as Hodgkin’s lymphoma. Autoantibodies against
amphiphysin and gephyrin have been identified in the serum of
patients with paraneoplastic SPS.2, 9, 10
Clinical criteria for diagnosing SPS were last revised in 20092 as
new discoveries regarding the pathophysiology of the disorder
were made (Table 3). Beyond these diagnostic criteria, clinical
response to diazepam is often included in the clinical criteria for
the diagnosis of SPS.

Table 2. Autoantibodies associated with stiff person syndrome
Autoantibody

Function of Target Protein

Anti-GAD65

Rate-limiting enzyme in the synthesis of GABA

Anti-Amphiphysin

Synaptic vesicle protein involved in the recruitment of dynamin to sites
of clathrin-mediated endocytosis which is involved in retrieving vesicle
membrane from axon terminals after exoctyosis of GABA

Anti-Gephyrin

Tubulin-binding protein involved in the clustering of GABAA and glycine
receptors at the postsynaptic membranes of inhibitory synapses

Anti-GABAA Receptor-Associated Protein (GABARAP)

Linker protein between gephyrin and GABAA receptors which is
involved in postsynaptic clustering and stability of GABAA receptors at
the post-synaptic membrane

Table 3. Dalakas diagnostic criteria for stiff person syndrome
Muscular rigidity in the limbs and axial (trunk) muscles, prominent in the abdominal and thoracolumbar paraspinals leading to a fixed
deformity (hyperlordosis)
Continuous co-contraction of agonist and antagonist muscles, confirmed clinically and electrophysiologically
Episodic spasms precipitated by unexpected noises, tactile stimuli, or emotional upset
Absence of any other neurologic disease that could explain the stiffness and rigidity
Positive anti–glutamic acid decarboxylase (or amphiphysin) antibodies assessed by immunocytochemistry, Western blot,
or radioimmunoassay
Adapted from: Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 2009;11:102-10.
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Table 4. Treatment options for patients with stiff person syndrome
GABA-Enhancing Drugs
Benzodiazepines (e.g. diazepam, clonazepam,
alprazolam, lorazepam)

diazepam: 5-100 mg; clonazepam:
2.5-6 mg; alprazolam: 2-4 mg;
lorazepam: 6 mg

Central GABAA agonist

Antiepileptic drugs (e.g. vigabatrin, valproate, gabapentin,
levetiracetam, tigabine)

vigabatrin: 2-3 g; valproate: 0.6-2 g;
gabapentin 3600 mg; levetiracetam:
2000 mg; tigabine: 6 mg

Augmentation of GABA signaling

Baclofen

10-60 mg

GABAB agonist

Tizanidine

6 mg

Central α2-adrenergic action;
inhibits norepinephrine release

Dantrolene

200-400 mg

Dissociates excitation-contraction
coupling and blocks release of Ca2+
from the sarcoplasmic reticulum

Botulinum toxin A

–

Neuromuscular junction blocking;
prevents acetylcholine exocytosis

IV immunoglobulin

2 g/kg

Immunosuppression/modulation

Rituximab

2 g (in two divided doses)

B-cell depletion

Plasmapheresis

5-6 passes

Immunosuppression/modulation

Corticosteroids

Up to 60 mg

Immunosuppression/modulation

Immunosuppressive agents (e.g. azathioprine,
methotrexate, mycophenylate mofetil)

azathioprine: 2.5-3 mg/
kg; methotrexate: 15-20 mg;
mycophenylate mofetil: 2-3 g

Immunosuppression/modulation

Antispasticity Agents

Immunotherapies

Adapted from: Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 2009;11:102-10

SPS is strongly associated with a variety of other autoimmune
disorders, and the presence of these co-morbidities can be helpful
in correctly diagnosing SPS. Autoimmune diabetes occurs
in up to 35% of patients with SPS.2 In addition to anti-GAD
antibodies, islet-cell antibodies have also been detected in the
serum of patients with SPS and diabetes.12 Other autoimmune
disorders, including thyroiditis, pernicious anemia, and vitiligo,
have also been observed in patients with SPS. Patients with SPS
presenting with these co-morbid autoimmune conditions have
elevated levels of their respective autoantibodies, including
thyroglobulin antibodies, thyroid peroxidase antibodies, and
gastric parietal-cell antibodies.12
Historically, the mainstays of treatment for SPS were
GABA-enhancing medications and anti-spasticity drugs.
However, as the autoimmune pathogenesis of SPS was identified,
the utility of immunotherapy for SPS was investigated and
has been validated. Currently, treatment of SPS consists of a
combination of GABA-ergic and anti-spasticity medication as
well as immunotherapy (Table 4).2
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Key Points
This patient’s case displays many of the clinical features classically
observed in SPS. There was a prodrome of severe anxiety and
she was able to identify a significant psychological stressor that
triggered her functional decline. She developed progressive
stiffness of the axial muscles leading to hyperlordosis and then
developed stiffness of the extremities with the lower extremities
locked in extension and upper extremities locked in flexion. She
also had painful spasms elicited by auditory or tactile stimuli
and she displayed autonomic instability on telemetry. She had
markedly elevated anti-GAD65 antibodies and had co-morbid
autoimmune disorders (autoimmune thyroiditis, latent
autoimmune diabetes of adults) with associated circulating
autoantibodies. Finally, she showed clinical improvement after
treatment with diazepam.
Unfortunately, our patient did not display any clinical
improvement following treatment with IVIG. However, in
the clinical trial that demonstrated benefit of IVIG therapy for
patients with SPS, bedridden patients were excluded.13 Thus,
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this case highlights the importance of early diagnosis of this
severely debilitating neurologic condition, as the least disability
is observed in patients treated early in the course of their disease.
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A Case Study of Pseudo-Neuropathic Pseudogout
Christina C. Lindenmeyer, MD, Adam Sobel, MD, Levon Nazarian, MD, Steven Mandel, MD,
Steven M. Raikin, MD, Homyar Karanjia, DPM

Background
This interesting case highlights the clinical progression of a rare
disease process and the important role of a multi-disciplinary
team in achieving a diagnosis and successful management plan.

Case Presentation
A 76-year-old male with a history of coronary artery disease,
hypertension and hyperlipidemia presented as an outpatient
with left foot pain and swelling. He had spent a week bicycling
in Colorado one month prior to presentation. The pain was
initially localized to the plantar surface of his foot and progressed
to involve the lateral and dorsal aspects of the foot, as well as his
great toe. The pain was accompanied by swelling of the midfoot
without erythema and he was unable to bear weight. His podiatrist
prescribed Ibuprofen and a foot brace for empiric treatment of
tendonitis. An outpatient MRI demonstrated extensive bony
edema and synovial enhancement within the midfoot, as well
as severe superficial edema and peroneal tendonitis with mild
subluxation. The patient was sent to the emergency department
to be evaluated for osteomyelitis.
On exam, the patient was afebrile with normal vital signs. The
left foot was warm and edematous without erythema or discrete
fluid collection. There were no ulcers or breaks in the skin. The
dorsal portion of the foot was exquisitely tender to palpation. The
ankle had decreased active and passive range of motion. Pedal
pulses were equal, and sensation was intact. Initial chemistries
were significant for an erythrocyte sedimentation rate (ESR) of
81 mm/hr and C reactive protein (CRP) of 1.1 mg/dL. Foot and
ankle x-rays were negative for fracture or dislocation. Venous
ultrasound of the lower extremities was negative for deep venous
thrombosis.
The patient was evaluated by orthopedic surgery and was
diagnosed with severe bony stress and trauma from his prolonged
bike trip. A full rheumatologic evaluation was normal. A fluid
collection amenable to arthrocentesis was not identifiable. Based
on imaging and physical exam, the Infectious Disease team did
not feel there was evidence of osteomyelitis. The patient was
prescribed high-dose Ibuprofen to treat inflammation caused
by bony trauma and placed in an air boot. The patient’s pain and
edema improved and he was discharged.
Two weeks later, the patient presented with worsening left foot
pain, edema, and continued inability to bear weight. He was
noted to have new left calf atrophy, but proximal and distal
muscles of the legs had full strength. Laboratory results were
significant for a leukocytosis of 11.7 B/L, CRP of 2.2 mg/dL, and
ESR of 94 mm/hr. A left foot x-ray demonstrated progression
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of left foot swelling, osteoporosis, and intertarsal joint erosions.
An MRI of the lumbosacral spine to evaluate for nerve root
compression did not identify any mass or abnormal signal
along the lumbosacral plexus. An MRI of the left foot and ankle
demonstrated unchanged bone marrow edema. No drainable
fluid collection was identified, and there was no evidence of
osteomyelitis. A bone scan demonstrated abnormal activity
within the left midfoot consistent with neuropathic joint disease
and synovitis of the left knee. Orthopedic surgery was consulted,
and additionally diagnosed micro-fractures of the midfoot,
visible on the left foot x-ray and MRI. Their diagnosis was
neuropathic joint disease and they recommended non-weightbearing status for joint preservation.
The patient developed progressive left knee edema and posterior
tenderness to palpation. An ultrasound of the left leg and ankle
demonstrated a Baker cyst, as well as chondrocalcinosis in
the cartilage of the talar dome and extensive synovitis of the
talonavicular and tarsometatarsal joints (Figures 1,2). Results
were discussed with Neurology and Radiology and a diagnosis
of pseudogout of the left knee, foot and ankle was made.
Rheumatology recommended high dose scheduled Naproxen.
The patient’s pain and edema improved, and he was discharged
home with Naproxen and an orthopedic boot.

Outcome and Follow-up
Two weeks after discharge, rheumatology aspirated three
milliliters of straw-colored fluid from the left ankle, which
contained calcium pyrophosphate crystals, consistent with
pseudogout. An ultrasound four months later demonstrated
improvement in the left talonavicular and tarsometatarsal joint
synovitis, and a small tibiotalar joint effusion with persistent
chondrocalcinosis. The patient’s outpatient orthopedic surgeon
confirmed the diagnosis of pseudogout, with associated pseudoneuropathic joint disease. The patient is currently being
maintained on low dose scheduled Naproxen and Methotrexate
as an outpatient. He is no longer wearing an orthopedic boot,
and is progressively regaining his mobility.

Discussion
This case highlights the importance of an evolving differential
diagnosis, based on physical exam, laboratory and radiological
tests. The initial outpatient differential diagnosis included severe
multifocal stress response, osteomyelitis, and early neuropathic
change, and evolved to include reflex sympathetic dystrophy,
osteoporosis and finally pseudogout with associated neuropathic
joint disease.
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Figure 1. Color Doppler Ultrasound, sagittal view of Figure 2. Ultrasound, sagittal view through the tibiotalar joint, showing
the talonavicular joint, showing thickened synovium cartilage calcification (arrow) at the talar dome, diagnostic of chondrocalcinosis
and increased color Doppler flow, indicating synovitis.
Calcium pyrophosphate dehydrate (CPPD) crystal deposition,
and ensuing crystal-induced synovitis, is an important pathologic
entity that is part of a spectrum of disease. This includes
pseudogout, or acute attacks of CPPD synovitis, chondrocalcinosis, or radiographically evident deposition of CPPD crystals,
and CPPD arthropathy, or chronic joint disease that typically
accompanies CPPD crystal deposition. This disease process
has important epidemiologic implications, as estimates suggest
an age-related rise in prevalence of related chondrocalcinosis.1
CPPD crystal formation is thought to initiate near the surface
of chondrocytes and may be related to purely elevated levels
of calcium, pyrophosphate, or local cartilage matrix changes
that enhance calcium or pyrophosphate levels. Most cases are
idiopathic, but some are associated with an underlying disorder.
Hemochromatosis, hyperparathyroidism, hypophosphatemia,
hypomagnesemia, familial hypocalciuric hypercalcemia,
Gitelman’s syndrome, gout, and hypothyroidism have been
shown to be associated with CPPD. Joint trauma or joint instrumentation is also an important etiology.2,3
Definitive diagnosis of CPPD crystal deposition disease is
made by synovial fluid analysis. Microscopy of aspirated fluid
will demonstrate the presence of positively birefringent CPPD
crystals. CPPD crystal deposits can be imaged by plain film
radiography as linear radiodensities in joint cartilage, ligaments
and joint capsules.4 Ultrasound imaging can also be used to
diagnose CPPD deposition disease. CPPD crystals will appear as
hyperechoic bands along the cartilage surface or as hyperechoic
spots in the fibrocartilage.5

There are few cases of CPPD crystal deposition disease associated
with severe joint degeneration resembling neuropathic
arthropathy and Charcot joint. This rare condition that has
been termed “pseudo-neuropathic joint disease.” It has been
speculated that acute episodes of pseudogout and chondrocalcinosis can precede the development of Charcot arthropathy
through cartilaginous microfractures, which results in the
shedding of CPPD crystals into the joint cavity and progressive
joint destruction.6-8
In patients with acute CPPD crystal arthritis, the CPPD crystals
should be removed by arthrocentesis. Intra-articular injection of
glucocorticoids is recommended in patients with no more than
two involved joints. When more than two joints are involved,
administration of oral non-steroidal anti-inflammatory (NSAID)
medications is recommended. For patients in whom NSAIDs
are contraindicated, colchicine can be used, and in patients for
whom NSAIDs and colchicine are contraindicated, systemic
glucocorticoids or immunomodulators such as methotrexate
can be used. Joint immobilization is the mainstay of therapy
for pseudo-neuropathic joint disease in order to prevent the
development of microfractures and joint collapse.9

Key Points
Pseudo-neuropathic pseudogout is a rare disease process that
can be difficult to elucidate. The key to diagnosis is arthrocentesis of the involved joint and the identification of calcium
pyrophosphate crystals in the synovial fluid. Ultrasound is a
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sensitive and specific technique for identifying chondrocalcinosis in a patient with suspected neuropathic joint disease.
The mainstay of treatment is NSAID therapy.
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Uncommon Hepatic Sequelae from an Acute Sickle Cell
Crisis
Kimberly Lim, MD, James Walter, MD

Background
Sickle cell crises are commonly treated at our institution given
its large sickle cell patient population and well-established
hematology department. While pain management is a crucial
aspect to these patients’ care, it is important to remember that
a vaso-occlusive crisis can be life threatening. Many organs
can be at risk, including the lungs (acute chest syndrome),
brain (stroke), eyes (retinopathy) and as in our case, the liver.
We hope this case report can become incorporated in future
differential diagnoses pertaining to sickle cell crises.

Case Presentation
A 48-year-old black female with a past medical history of
sickle cell anemia, HIV on antiretroviral therapy, pulmonary
hypertension on 4L of home oxygen, lymphocytic interstitial
pneumonitis, chronic obstructive pulmonary disease, remote
history of deep vein thrombosis, and pulmonary embolism,
presented to the emergency department with complaints of
shortness of breath, increased abdominal girth and lower
extremity swelling for four days. She also complained of
lower back and leg pain typical of her sickle cell crises. Her
prescribed medications included tenofovir/emtricitabine,
atazanavir, ritonavir, folic acid, oxycodone/acetaminophen,
oral hydromorphone, and furosemide. Her social history was
significant for smoking one fourth of a pack of cigarettes daily.

Investigations
On presentation her vitals were temperature 98.1°F, blood
pressure 106/48 mmHg, heart rate 87 beats per minute, and
respiratory rate 19, with an oxygen saturation of 88% on 4L of
oxygen by nasal cannula. Her physical exam revealed scleral
icterus, diffuse abdominal pain most pronounced in the right
upper quadrant to palpation, hepatomegaly and abdominal
distention. She did not have any lower extremity edema. Her
initial labs showed a total bilirubin of 49.4 (mg/dl), direct
bilirubin 42 (mg/dl), AST 165 (IU/L), ALT 110 (IU/L), alkaline
phosphatase 434 (IU/L), ammonia level 150 (mcmol/L). Her
coagulation studies were partial thromboplastin time (PTT)
32, and an international normalized ratio (INR) of 1.9. She
was also found to have a hemoglobin of 6.6 g/dL (down from
9 g/dL three days prior to presentation), white blood cell count
of 13.6 (B/L) and platelet count of 276 (B/L). Additionally,
the Hemoglobin S (HgS) percentage was 90%. Her creatinine
was 2.8 (mg/dL), urea nitrogen 74 (mg/dL), potassium 6.2
(mmol/L), bicarbonate 6 (mmol/L), anion gap of 25. Her

other serum electrolytes were within normal limits. Her lactate
dehydrogenase was 1405 (IU/L) and haptoglobin <10 (mg/
dL). Her ABG showed a pH of 7.2, pCO2 24 (mm Hg), pO2 91
(mm Hg). Lactate was 8.4 (mmol/L). Her CD4 count was 432.
A limited abdominal ultrasound showed cholelithiasis with gall
bladder sludge, but normal wall thickness and no pericholecystic
fluid. The liver measured 22.1 cm in sagittal length consistent
with hepatomegaly, but showed normal echogenicity and
texture. There was no intra or extrahepatic bile duct dilatation.
Renal ultrasound showed no hydronephrosis. An echocardiogram showed a pulmonary artery systolic pressure of 90
mm Hg, normal left ventricle systolic function, right ventricle
enlargement and decreased function, but no significant changes
from a prior echocardiogram.

Differential Diagnosis
Table 1 highlights our initial broad, problem-based, differential
diagnosis. In terms of the workup of her liver failure, the
differential was narrowed by the aforementioned lab findings
and imaging. The abdominal ultrasound did not show signs of
biliary obstruction or thrombus. Hepatitis panels and initial
screening for medication induced liver failure were negative.
Given her initial liver function elevations and lactic acidosis,
it was thought that a vaso-occlusive hepatic crisis was most
likely the etiology of her liver failure. Tenofovir, known to
cause a severe lactic acidosis, was initially held. The patient was
empirically started on broad-spectrum antibiotics, but with
negative bacterial cultures and lactic acid resolution following
appropriate intervention, the vaso-occlusion from sickled red
blood cells (RBC) leading to end organ ischemia was believed
to be the most likely etiology. Likewise, this would also explain
the pathogenesis behind her renal failure.
The patient was admitted to the medical intensive care unit.
A femoral pheresis catheter was urgently placed and she
received six units of red blood cell exchange transfusion. Her
Hemoglobin S percentage decreased to 42% from 90% after the
transfusion and her hemoglobin increased to 9.4 (g/dL), while
total bilirubin decreased to 36.3 (mg/dl) and direct bilirubin
29.4 (mg/dl).

Outcome and Follow-up
Once stabilized, the patient was transferred to the general
medicine floor for routine care. Her hospital course included
episodic shortness of breath and hypoxia, which improved with
diuresis. Five days after presentation, her total bilirubin reached
a nadir of 9.4 (mg/dl), with a direct bilirubin of 6 (mg/dl) and
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AST / ALT levels of 76 (IU/L) and 140 (IU/L) respectively. Her
creatinine stabilized at 1.6 (mg/dL) from a peak of 3.2 (mg/dL)
at time of discharge.

Discussion
Sickle cell disease (SCD), as a hemoglobinopathy, can cause
widespread sickling and vaso-occlusive events in all organ
systems. Although not as commonly seen, liver involvement
can be life threatening. Sickle cell hepatopathy has been a
term used to generally describe varying etiologies of liver
dysfunction in sickle cell patients. Multiple blood transfusions
subject patients to increased risk of infectious processes, such
as hepatitis B and C, and iron overload. Chronic hemolysis also
causes sickle cell patients to be more prone to development of
pigmented gallstones, which can lead to acute cholecystitis and/
or biliary duct obstruction. Hepatic sequestrations can cause
hepatic enlargement and rapidly falling hemoglobin. These
complications can present similarly to acute sickle hepatic crisis
and need to be excluded to make a diagnosis.1-4
Acute sickle hepatic crisis has been seen in about 10% of patients
with SCD. Common presenting symptoms include right upper
quadrant pain, low-grade fever, tender hepatomegaly, jaundice
and elevated liver function tests. The pathogenesis stems
from sickle cell thrombi in the sinusoidal space leading to
ischemia. In a more extreme form, this can lead to intrahepatic
cholestasis, which is rooted in widespread ischemia secondary
to a massive sickled RBC load leading to hepatocyte edema
and obstructive biliary outflow.2 AST/ALT levels can run in the
thousands, with total bilirubin levels reported as high as 300.5
Coagulopathy is common and worsens as hepatocyte necrosis
spreads. Histological hallmarks include sickle cell thrombi
within sinusoids that can lead to bile plugs formation in
canuliculi, inflammatory cell infiltration and hepatocyte edema/
necrosis from prolonged ischemia. Such hepatic damage makes
the prognosis of sickle cell intrahepatic cholestasis poor. Of
the limited published cases report, mortality from intrahepatic
cholestasis is greater than 50%.5
The cornerstone treatment for intrahepatic cholestasis is
rapid HgS fraction reduction. While there are no specific
studies looking at target fractions in acute hepatic sickle cell
crises, previous studies focusing on stroke risk in sickle cell
patients show risk reduction with HgS fractions less than 30%.6
Reduction can be achieved through exchange transfusion
using pheresis, which allows for better fluid management and
avoids rapid changes in volume that can impact intravascular
viscosity. Additional supportive treatment includes hydration,
pain management, coagulopathy correction, and electrolyte
monitoring.
Liver transplantation has been proposed as a therapeutic option
in patients with fulminate failure from an acute crisis.7 However,
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transplantation experience is very limited. Only 18 transplant
cases have been reported in the literature. 7 Hepatic vascular
re-thrombosis and associated phenomenon (i.e. neurovascular
injury) from post-operative sickle cell crises add to the inherent
morbidity/mortality risk.7 Consequently, the overall mortality
rate in SCD patients with acute hepatic failure undergoing
transplant is 60%.6 Optimization of post-operative management
will improve as transplantation is considered early in patients
where fatal hepatic failure is anticipated.
Given the clinical presentation of our patient, she showed signs
of ischemia with an elevated lactate, liver and kidney failure.
Her hepatitis panels were negative, and ultrasound showed
no signs of obstructive disease. Given her significant direct
hyperbilirubinemia, it was thought that she was suffering from
acute intrahepatic cholestasis causing liver and renal failure.
This was confirmed by her immediate improvement after red
blood cell exchange transfusion. This case reiterates the need
for early detection of liver involvement in sickle cell disease.
Early management with exchange transfusion usually prevents
potentially fatal liver failure.1

Key Points
• Acute sickle cell hepatic crisis is an uncommon, but potentially
fatal sequela of sickle cell disease if not diagnosed early in the
disease course.
• Common findings include profound jaundice, hepatomegaly,
high AST / ALT, total bilirubin and renal failure.
• Primary therapy is aimed at rapid reduction of the HgbS
fraction through exchange transfusion via pheresis.
• Liver transplantation is a possible option in patients with
fulminant hepatic failure.
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A 73-Year-Old Female With Palpitations

Kevin Curl, MD, Jacqueline Kraft, MD, Malinda Wu, MSIII, Carlos Fernandez-Ortega, MSIII

Background
Atrial fibrillation is a commonly encountered clinical
problem. Although a large percentage of patients have no
clearly identifiable precipitant, secondary atrial fibrillation is a
well-documented clinical entity.1

Case presentation
A 73-year-old female with a history of obstructive sleep apnea,
hypertension, and chronic obstructive pulmonary disease
presents with complaints of intermittent palpitations, substernal
squeezing chest pressure, and shortness of breath for two weeks.
Her most recent episode occurred on the bus, prompting her to
come to the emergency room for evaluation. Further questioning
revealed mild weight loss and diarrhea over the prior few weeks.
Home medications included amlodipine, baby aspirin, albuterol
as needed, and ciprofloxacin for a recently diagnosed URI.

Investigation
Vital signs were temperature 99.4°F, blood pressure 140/70,
heart rate 154, respiratory rate 14, with oxygen saturation of
95% on room air. Physical exam revealed scattered bilateral
rhonchi, irregularly irregular tachycardia, and mild lower
extremity edema. Electrocardiogram (ECG) showed atrial
fibrillation with a ventricular rate of 137 bpm and non-specific
ST/T wave changes. Initial laboratory studies showed negative
cardiac markers, normal blood counts, and normal basic
metabolic panel. Transthoracic echocardiogram on hospital day
1 was remarkable for a normal ejection fraction (65%) without
segmental wall motion abnormalities, severely dilated left
atrium (left atrial volume Index 43 cc/m2), mild left ventricular
hypertrophy, and no significant valvular abnormalities.
Further lab studies revealed a thyroid-stimulating hormone
(TSH) less than 0.01mIU/mL and free thyroxine (fT4) of 4.1
ng/dL (0.7-1.7 ng/dL). Endocrinology was consulted and
recommended empirically starting methimazole 10 mg three
times a day along with further thyroid laboratory investigation,
and a thyroid ultrasound. Total triiodothronine (T3) was
325ng/dL (90-180ng/dL), free T3 was 15.3pg/dL (2-4.4 pg/
dL), and thyroid ultrasound revealed a rounded homogeneous
thyroid without any dominant nodules greater than1cm. A
thyroid uptake scan (Figure 1) exhibited rapid iodine turnover
consistent with Graves’ disease. Eventually, thyroid stimulating
immunoglobulin returned at a level of 620% (normal <140%)

and anti-thyroid peroxidase antibody level was 530.5 units
(0-100 units).

Treatment
The patient’s heart rate was initially controlled with intravenous
beta-blockers. She was fully anticoagulated for her new-onset
atrial fibrillation. The patient’s rate control improved with oral
metoprolol in addition to methimazole. She spontaneously
converted to sinus rhythm on treatment day 3 of this regimen.
Her heart rhythm remained in sinus throughout the rest of
her hospitalization, and she was discharged with a enoxaparin
to warfarin. She was asked to follow-up with endocrinology
as an outpatient to discuss further treatment options for her
hyperthyroidism, including possible radioactive ablation.

Outcome and follow-up
The patient has been seen in follow-up in the cardiology clinic.
Office exam and ECG revealed frequent atrial ectopy and it
is possible that this patient has subclinical paroxysmal atrial
fibrillation episodes. She is rate controlled with metoprolol and
is anticoagulated with warfarin, which she is to continue for three
months. After three months, a one week outpatient telemetry
will be ordered to assess her burden of atrial fibrillation. Should
she be free of atrial fibrillation, the possibility of discontinuing
her warfarin and maintaining her on aspirin mono-therapy will
be discussed with the patient.

Figure 1. Thyroid uptake scan showing diffuse thyroid uptake
without a dominant “hot” nodule. These findings are consistent
with Graves’ disease.
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Discussion
Atrial fibrillation is the most common arrhythmia in patients
with thyrotoxicosis. Prevalence of atrial fibrillation in hyperthyroidism ranges between less than 2% to 20%.1,2 Increasing
age, male sex and structural heart disease, such as ischemic
heart disease, congestive heart failure and valvular disorders
(especially mitral valve prolapse), are associated with increased
risk of atrial fibrillation in patients with hyperthyroidism. 3
While it is common for hyperthyroid patients to develop atrial
fibrillation, less than 1% of all atrial fibrillation patients have
hyperthyroidism.4
The mechanism by which hyperthyroidism predisposes to atrial
fibrillation has not been clearly identified.1 Thyroid hormone
shortens cardiomyocyte refractory period by upregulating the
transcription of β-adrenergic receptors, resulting in an increased
cAMP that subsequently accelerates diastolic depolarization
and increases heart rate. Thyroid hormone shortens the action
potential duration of isolated rabbit pulmonary vein cardiomyocytes, which decreases refractoriness and facilitates the genesis
of reentrant circuits, thereby increasing the arrhythmogenic
activity of pulmonary vein cardiomyocytes.5

Key Points

The cardiovascular manifestations of hyperthyroidism are
best corrected by treating the underlying thyrotoxicosis with
either antithyroid drug therapy or radioactive iodine thyroid
ablation.1 Pharmacotherapy with methimazole or propylthiouracil can provide a more rapid reduction in serum T4 and T3
than radioactive iodine ablation and is often utilized to prevent
the potential thyrotoxicosis exacerbation that can occur with
therapeutic doses of radioidodine.6 Methimazole is typically
preferred to propylthiouracil, except during the first trimester
of pregnancy, because it can more rapidly reverse thyrotoxicosis
and has fewer side effects. Both serum T4 and T3 should be
monitored in the treatment of thyrotoxicosis because serum T3
concentrations may remain elevated even with normalization
of serum T4.7 In comparison with the importance of serum T3
and T4 values, serum TSH values may be misleading during the
initial period of treatment.8
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Patients under 60 years of age without preexisting heart disease
and short duration thyrotoxicosis typically spontaneously
convert to normal sinus rhythm within 6 weeks; the frequency
of conversion decreases in older patient populations, who
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frequently require interventions. 9 The treatment of atrial
fibrillation in thyrotoxicosis should be limited to rate control,
as cardioversion and normal sinus rhythm cannot be reliably
maintained while thyrotoxicosis persists. 1 Patients who
experience atrial fibrillation as a complication of thyrotoxicosis are at increased risk of thromboembolism, and should
be anticoagulated according to non-valvular atrial fibrillation
guidelines. Because thyrotoxicosis is associated with increased
plasma clearance of vitamin K-dependent coagulation factors,
the dose of warfarin required to achieve full anticoagulation in
these patients is lower.10

Patients presenting with arrhythmias should be screened for
thyroid dysfunction. These arrhythmias are best corrected
with treatment of underlying thyroid disease. Atrial fibrillation
secondary to thyrotoxicosis should be treated with rate control,
as cardioversion cannot reliably maintain sinus rhythm.
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A Young Female Who Develops Tachycardia and
Orthostatic Intolerance Following a Recent Infection
Michael A. Valentino, MD, PhD

Case Presentation

Investigations

The patient is a 20-year-old female with a history of asthma
and anxiety with panic attacks who presented with palpitations
and lightheadedness/pre-syncope. The morning of admission,
she was attending a seminar and experienced an acute onset
of palpitations. The palpitations started while she was seated
and worsened upon standing. They were associated with
lightheadedness, shortness of breath, and chest tightness. A
nurse attending the seminar recommended that she go to the
emergency room.

On physical exam, she was in no acute distress. She had moist
mucous membranes and no conjunctival pallor. Her cardiac
exam was remarkable only for tachycardia. The rest of her exam
was unremarkable. Orthostatic vitals were checked revealing a
BP of 130/75 and HR of 90-110 beats per minute (bpm) while
sitting and a BP of 145/97 and HR of 130-150 bpm while standing,
with associated lightheadedness and shortness of breath.

On presentation to the emergency department (ED) her vital signs
were: Temperature: 99.2°F, Blood pressure (BP): 140/98; Heart
rate (HR): 140; Respiratory rate (RR): 16; Oxygen saturation:
100% on room air. She reported that she had experienced
prior panic attacks but that this episode was persistent and
significantly more intense in comparison. She also reported that
a few days prior to presentation she had completed a prolonged
course of antibiotics for tonsillitis. Her only medications were
oral contraceptive pills (OCPs) and dextroamphetamine/
amphetamine (Adderall®). She reported taking her Adderall® as
prescribed, most recently on the day prior to presentation. She
denied other stimulant or illicit drug abuse. Her family history
was significant for anti-phospholipid antibody syndrome (APS)
in her mother.

Differential Diagnosis
The differential diagnosis included cardiac tachyarrhythmia
(e.g. supraventricular tachycardia, atrial flutter/fibrillation),
dehydration, anemia, hyperthyroidism, hypoglycemia,
pharmacologic stimulant abuse, infection, and pulmonary
embolism. An electrocardiogram (ECG) revealed sinus
tachycardia (Figure 1) with no significant ST-T wave changes.
Labs drawn on admission revealed normal blood counts and
chemistries, and her thyroid panel revealed an elevated thyroid
stimulating hormone but normal free T3 and free T4 levels. A
urine drug screen was positive for amphetamines, consistent
with her reported use of Adderall® the day prior to presentation.
Given the acuity of onset of her symptoms, her family history of
APS, and her OCP use there was a high suspicion for pulmonary

Figure 1. Patient’s admission ECG
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embolism, which was subsequently ruled out with a ventilation/
perfusion scan. She received two 1-liter saline boluses in the ED
for suspected dehydration, and she was admitted to the general
medicine service.
The next morning the patient continued to exhibit orthostatic
intolerance with significant tachycardia upon standing and
ambulating, associated with shortness of breath and lightheadedness/dizziness. Since the initial workup was negative and
her orthostatic tachycardia continued, the Electrophysiology
service was consulted. Their differential diagnosis included:
amphetamine-induced tachycardia, other exogenous
stimulants, and inappropriate sinus tachycardia. However,
given the patient’s orthostatic tachycardia with normal BP, her
age, gender, and recent infection, the most likely diagnosis was
postural orthostatic tachycardia syndrome (POTS).

Outcome and Follow-up
On the second day of the patient’s admission, her tachycardia
improved. Her HR while ambulating peaked in the 110s
associated with only mild shortness of breath. The decision
was made not to treat with beta-blockers or calcium channel
blockers since she remained hemodynamically stable and only
minimally symptomatic. She was instructed to discontinue the
Adderall® and avoid any other stimulants, including caffeine. She
was to follow-up with Electrophysiology at Thomas Jefferson
University Hospital and to schedule an outpatient tilt table test.

Discussion
Orthostatic intolerance is defined as cerebral hypoperfusion or
sympathetic activation while standing, relieved by recumbency.
POTS is a clinical syndrome characterized by orthostatic
intolerance without orthostatic hypotension.1 The accepted
definition of POTS is orthostatic intolerance with a rise in HR of
>30 bpm within 10 minutes of head-up tilt or standing, or a HR
of >120 bpm while upright, without orthostatic hypotension.2
The majority of patients with POTS are young females, with an
average age of 30 years.3 The most common symptoms are those
related to cerebral hypoperfusion and sympathetic activation.1
Fatigue is also a common symptom, and many patients have
poor exercise tolerance.1 While most patients cannot identify
an inciting event, some patients recall an antecedent viral
illness, while others associate the onset of symptoms with recent
surgery or trauma.1,4
Several pathophysiologic mechanisms have been proposed to
underlie POTS. About 50% of patients with POTS have regional
autonomic denervation, typically in the lower limbs. Sympathetic
denervation of the lower extremities, as demonstrated by a
quantitative sudomotor axon reflex test (QSART), thermoregulatory sweat test, and impaired norepinephrine spillover in the
lower extremities in response to various stimuli, can cause loss of
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vasomotor tone and pooling of blood in the legs.3,5 This can cause
a decrease in preload upon standing and a reflexive increase in
sympathetic stimulation of the heart in order to maintain cardiac
output. The cause of this peripheral sympathetic denervation is
still unclear, but ganglionic (α3) acetylcholine receptor (AChR)
antibodies have been demonstrated in ~15% of patients with
POTS indicating a possible autoimmune mechanism.3
Another subset of POTS is characterized by a hyperadrenergic
state with elevated plasma norepinephrine levels (>600 pg/mL)
and a rise in BP on standing.4 In a recent study, 29% of patients
with POTS had elevated plasma levels of norepinephrine upon
standing, and these patients benefited the most from β-blockade.3
In some patients, hypovolemia may also contribute to the
manifestation of POTS. Dysfunction of the renin-angiotensinaldosterone system has been implicated as a cause of the
hypovolemia observed in some patients with POTS, as these
patients lack a compensatory increase in circulating renin and
aldosterone despite low plasma volume.6,7
Several investigations should be made to establish the diagnosis
of POTS including: orthostatic vitals (head-up tilt or standing),
QSART response, thermoregulatory sweat test, supine and
standing norepinephrine measurements, and 24-hour urine
sodium excretion (surrogate marker for plasma volume).3
Pharmacologic treatments for POTS are aimed at increasing
plasma volume (fludrocortisone, erythropoietin), enhancing
venous return to the heart (midodrine, octreotide), or
counteracting a hyperadrenergic state (β-blockers, clonidine,
pyridostigmine, disopyramide).3,4 Nonpharmacologic treatments
for POTS include high salt intake, water repletion, small
frequent meals, regular exercise, and compression stockings.
Typically, treatment is tailored toward the suspected underlying
mechanism determined from autonomic testing.

Key Points
POTS is a disorder that is most common in young females
and characterized by orthostatic intolerance without a decline
in blood pressure. The syndrome may have several etiologies,
which include peripheral denervation with lower extremity
pooling of blood, a hyperadrenergic state, and low plasma
volume. In a significant number of patients, the symptoms of
POTS are manifested shortly after an infection, as occurred in
our patient’s case, or following other stressful events such as
surgery or trauma. Initial work-up includes ruling out common
etiologies for tachycardia, including: cardiac tachyarrhythmia,
anemia, stimulant abuse, dehydration, pulmonary embolism,
and hyperthyroidism. The patient should have orthostatic vitals
measured or undergo a formal tilt table test. An increase in
HR of >30 bpm or a HR of >120 bpm upon standing, without
orthostatic hypotension, correlates with a diagnosis of POTS.
The patient should then undergo autonomic testing as outlined
above to determine the etiology of the patient’s orthostatic
intolerance and determine the most appropriate therapy.
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Metastatic Uveal Malignant Melanoma: A Case Report
James Walter, MD, Rebecca Matro MD, and Daniel Quirk, MD, MPH

Case Report
A 77-year-old woman presented with a chief complaint of
one day history of severe, acute abdominal pain. The patient
described the pain as “intense,” non-radiating, and located
primarily in the left upper abdominal quadrant. The pain was
associated with nausea and multiple episodes of non-bilious,
non-bloody emesis. She denied melena and hematochezia. On
physical examination, her abdomen was soft and exquisitely
tender in the left upper quadrant and epigastric regions. Aside
from trace lower extremity edema, the remainder of her physical
examination was unremarkable. Laboratory results at the time
of admission were notable for: hemoglobin 10.8 g/dL, alkaline
phosphatase 459 U/L, aspartate transaminase 56 U/L, and
alanine transaminase 66 U/L.
The patient’s past medical history was significant for
hypertension, gastroesophageal reflux disease, papillary thyroid
carcinoma, and right eye uveal melanoma. The ocular melanoma
was treated 16 years ago with radioactive plaque followed by
transpupillary thermal therapy. The patient was diagnosed
with metastatic disease to her liver approximately 6 years prior
and she had received several rounds of hepatic radiation and
chemotherapeutic embolizations. The patient’s oncologist
closely monitored her for disease progression through regular
abdominal imaging studies.

Figure 1. Metastatic malignant melanoma lesions within
gastric body.

An esophagogastroduodenoscopy revealed a normal esophagus,
numerous hyperpigmented flat to slightly raised lesions
throughout the stomach, particularly in the proximal body and
fundus (Figures 1, 2), and a 2 mm lesion in the duodenal bulb
Histopathology and immunohistochemical staining of these
lesions confirmed metastatic malignant melanoma (Figure 3).

Discussion
The incidence of cutaneous malignant melanoma is rising at
a rate faster than that of any other malignancy.1 Melanoma is
notorious for its aggressive ability to metastasize to nearly every
part of the body, with the liver, lung, and bone being the most
common sites.2 With specific regards to uveal melanoma (UM),
it is the second most common form of melanoma. 3 Unlike
the cutaneous form, UM’s incidence rate has remained stable
over the years. UM can arise anywhere within the uveal tract
(iris, ciliary body and choroid) and spreads hematogenously.
Hematogenous spread is favored over lymphatic spread due to
the lack of sufficient lymphatic drainage.4,5
Melanoma’s particular affinity for metastasizing to the gastrointestinal (GI) tract has been well described in the literature. GI
involvement has been found in up to 60% of primary cutaneous

46

Figure 2. Closer endoscopic view of a lesion.
malignant melanoma patients at autopsy and is commonly
associated with invasive visceral organ disease. Given the highly
vascularized nature of the small bowel, it is the most common
site of GI tract metastasis. Stomach involvement comprises
approximately 20% of GI tract metastasis cases Antemortum
diagnoses of GI metastasis are made in only 1% - 4% of patients
with malignant melanoma . Such a diagnosis can go clinically
undetected until years after the initial diagnosis.6-8
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Symptoms of GI melanoma metastasis tend to be inconspicuous
and nonspecific. Patients may report vague abdominal pain,
weight loss, nausea/vomiting, and/or malaise. Anemia may also
be seen as a result of slow, chronic blood loss from ulcerated lesion
sites giving rise to melena. Such symptoms should raise suspicion
in patients with a known history of melanoma. However, with a
median survival time of less than six months after confirmed GI
involvement, the prognosis is generally very poor.6
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Figure 3. Biopsy histopathology showing invasion of malignant
melanocytes into gastric mucosa.
Endoscopically, metastatic melanoma can be polypoid in nature,
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act as lead points for intussusception. Submucosal nodules with
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Easing the Pain: An Argument for Prescribing Opiates in
Continuity Clinic
Lindsay Wilde, MD

Continuity clinic can be painful. The patients are often
non-adherent, the no-show rate is high, and the paperelectronic records hybrid system is less than ideal. Added to that
is the stress of caring for patients with a variety of medical issues
and the burden of being expected to prescribe opiates for them.
Given all of the difficulties associated with opiate prescribing,
including the potential for abuse, limited continuity with
providers, and poor overall adherence to medical advice, it
has been proposed that these medications should no longer be
prescribed at our resident clinic, and many residents support
this plan. However, implementing a blanket moratorium on
opiate prescribing would violate several of the fundamental
principles of our medical training.
According to U.S. Food and Drug Administration data,
approximately one hundred million new opiate prescriptions
were written in the year 2009. Of these prescriptions, general
internists were responsible for writing about fifteen percent
of them, including both immediate and extended release
formulations.1 So, if opiate use is so fraught with problems,
why are physicians prescribing so many of them? This is likely
because they are some of our most effective medicines and
many of our patients need immediate relief from acute pain.
There is a wealth of evidence that has shown opiates to be
effective in the management of acute pain. Eliminating opiate
prescribing in our continuity clinic would limit our ability to
provide comprehensive treatment to those patients with acute
pain needs. Similarly, it would deprive patients of adequate
pain control in the acute setting. In the spirit of practicing
evidence-based medicine, as well as upholding the core value of
beneficence, it is our responsibility to prescribe opiates to those
patients for whom the benefits outweigh the potential risks.
The ability to prescribe the full range of medications for pain
management is also a necessity for the residency program.
Residency training is designed to broaden the knowledge and
experience of new physicians. This includes an education
in appropriate pain management strategies. In fact, the
Accreditation Council for Graduate Medical Education lists
education in the use of common medications, including pain
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medications, as a requirement for the accreditation of all
internal medicine residency programs.2 While didactic sessions
are useful and necessary in fulfilling this requirement, there
is no substitute for first-hand clinical experience. Learning to
partner with patients in the clinic in order to manage their pain
and seeing their response to different therapies is an integral
part of our preparation for future practice. Regardless of our
career path, we will all be caring for patients who are in pain,
and it is imperative to know how to care for them. Continuity
clinic is one place where we must gain this knowledge.
It is without question that our current method of prescribing
opiates in clinic is imperfect. However, simply suspending the
practice would deprive us of a valuable quality improvement
opportunity. Reviewing the pain management literature,
creating an educational curriculum, developing a prescribing
policy, and implementing evidence-based monitoring practices
would not only serve as an important educational exercise, but
it would also help to alleviate many of the stressors that we face
in continuity clinic on a daily basis.
As residents, it is imperative that we remain dedicated to
expanding our medical knowledge and implementing evidencebased practices in order to provide our patients with the highest
level of medical care. Learning to uphold these fundamental
principles during our training will help to ensure that we
continue to do so for the duration of our medical careers.
Therefore, we should rethink the way we prescribe opiates
in clinic and, instead of prohibiting the practice altogether,
commit ourselves to improving what we do, both for the sake of
our education and for our patients.
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An Argument Against Prescribing Opiates in Continuity
Clinic
Hasan Bayat, MD

Chronic pain is one of the most common complaints a primary
care physician faces while in practice. As resident physicians at
Jefferson Hospital Ambulatory Practice (JHAP), it is a frequently
addressed concern, which ultimately leads to the question of
whether or not opiates should be prescribed at JHAP to those
patients who have failed non-narcotic alternatives.
The hesitation most physicians have in prescribing such
medications is the potential for abuse, addiction and diversion.
The Drug Enforcement Administration (DEA) shares these
concerns and consequently monitors and restricts the
prescription of opioids, stimulants and anxiolytics by requiring
a separate license. Most resident physicians choose to not
obtain a DEA license because of the cost, but also due to the
convenience of not having the responsibility that comes from
prescribing controlled substances.
In a European study evaluating the prescribing habits of general
practitioners, nearly a quarter refused to prescribe opioids for
persistent non cancer pain. Both prescribers and non prescribers
expressed concern over risks of opioids and believed to be
inadequately trained in treating chronic pain. To alleviate such
concerns, an institution sponsored training program in treating
chronic pain and assistance in obtaining a DEA license would
perhaps foster an environment that is more conducive to
prescribing narcotics at JHAP.
Even with appropriate training and the understanding that these
medications have a potential for abuse and diversion, misuse

of opiates is a common occurrence and growing problem. In
a prospective cohort study, the one-year incidence of opioid
misuse among patients enrolled in a chronic pain disease
management program within an academic internal medicine
practice was 32%.
Practicing in a tertiary care center allows us to utilize resources
that would otherwise be inaccessible in a community setting.
The Jefferson Pain Center is one of those resources dedicated
to providing comprehensive, pain-focused evaluation and
treatment of chronic pain. Referral to such a center would allow
patients to be treated by physicians trained specifically to deal
with their concerns in a setting with established guidelines and
protocols.
In light of such concerns for abuse, lack of training and
appropriate licensure, and the availability of alternative resources
at Thomas Jefferson University Hospital, the utilization of such
alternative resources for treatment of chronic pain would be
most appropriate for a resident physician practice such as JHAP.
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Discharge Summaries: How Long Is Too Long?
Kevin Curl, MD

The Graduate Medical Education (GME) committee is composed
of all Jefferson residency and fellowship program directors, as
well as ten selected housestaff members. The committee meets
monthly to discuss a wide array of topics, including Accreditation
Council for Graduate Medical Education compliance, duty hours
violations, and program reviews. One recently covered topic was
the timeliness of discharge summary dictations. Implementing
changes to improve transitions of care remains a focus of all
healthcare systems. Jefferson is attempting to take an innovative
approach to this issue, and discharge summaries are only one of
the areas being examined.
The current policy requires housestaff to dictate the discharge
summary within 14 days of discharge. Delinquent summaries
receive a monetary fine on a weekly basis. Attending physicians
have up to 120 days from discharge to finalize the summary,
which is currently not in line with the Joint Commission mandate
of finalized summaries within 30 days of hospital discharge.
With increasing emphasis on early outpatient follow-up, many
primary care physicians are seeing patients prior to having access
to the discharge summary. Because of the disparity between the
current policy and goal of timely clinical follow-up, Jefferson is
examining the current timeline to address this issue.
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At its September meeting, the committee heard a proposal to
alter the required time of finalizing the discharge summary to
17 days. Members discussed the appropriate allocation of the
seventeen days between housestaff and attending physicians.
Housestaff members were encouraged to voice their opinion
about changing the current 14 days to 10 or possibly 7 days.
The official recommendation of the committee was to preserve
the current 14 day policy for housestaff, while making necessary
adjustments to the attending policy.
After significant discussion and review by multiple hospital
subcommittees, the official policy was announced at the January
22nd, 2013 GME committee meeting. The time for hous staff
will remain unchanged at 14 days, and the attending policy will
change to 30 days from hospital discharge. Punitive measures
for delinquent attending finalized discharge summaries will
increase, including suspension and revocation of admitting
privileges. This policy was officially implemented in April 2013.
Undoubtedly, improving healthcare provider hand-off will
remain an area of focus throughout the healthcare system. The
Jefferson discharge summary policy will likely remain a target
for improvement in the future.
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Too Tall for Guatemala
Evan Lapinsky, MD

I was clearly out of place. I came to the highlands of Guatemala
during my fourth year of medical school to study Spanish, work
in a rural clinic, and experience a different way of life. For a
month, I lived with a Guatemalan family, ate plantains with
every meal, and generally tried to immerse myself in the rich
Mayan culture surrounding me. Almost a year later, my Spanish
is fading fast. The handful of days I spent in volunteer clinic is a
distant memory at this point. Why did I go there again?
I was the epitome of an outsider. I came down with Montezuma’s
revenge, just like all of my American classmates who traveled
there with me. Despite its location in tropical Central America,
Guatemala is an exceptionally mountainous country and
despite all the warnings from the program’s director about the
cool climate, I severely under packed. That left me living, eating,
and sleeping in my one Patagonia fleece. As a tall American, I
towered over the local people and fit very poorly in nearly all
things Guatemalan. I rode buses with my knees under my chin
and my head on the ceiling.
The coup de grace occurred while I was walking down a street
near my Guatemalan family’s home. One of the storefronts was
doing construction that involved scaffolding above the sidewalk,
which I had safely avoided, until now. This time, I walked smack
into a wooden beam at full clip. I was jolted backwards and fell
flat on my back. I had taken the impact right over the bridge
of my nose, where luckily I had been wearing a pair of sturdy
sunglasses. I’m convinced that were I not wearing them, I would
have broken my nose or knocked out some teeth. In any case,
this beam of wood—at over six feet above the ground—was

much too high to bother the locals as they all passed under it
with ease. Again, I was out of place—and fortunate to escape
with only some minor cuts and a bad headache.
I realized then that it was this feeling of foreignness, of not
belonging, that came to define my experience there. Living in
a foreign place freed me to approach my time in Guatemala
as something altogether different. I didn’t want to and really
couldn’t compare it to my American life because that would be
like comparing apples and oranges. The value was in recognizing
this disparity and taking Guatemala for what it was. It took
me several weeks, but I turned the corner while I still had the
chance to enjoy my time there. Accepting the discomfort is what
allows us to grow.
Mayan culture fascinated me, and I rekindled my love of
learning languages that had fallen by the wayside for a decade.
I took pleasure in exploring a new diet and helped my host
family’s children with their English homework. Interactions
with Guatemalan medicine showed me new approaches to
familiar problems, and the crippling limitations of third world
countries.
I don’t know if I will ever have another opportunity to immerse
myself in a different culture, but the future holds many more
challenges to my comfort zone. When I flew out of Guatemala,
I knew in my heart that I would never return—or that if I did,
it wouldn’t be the same. Still, that didn’t change what I learned
and how I felt while I was there. I was too tall, yes, but that’s
precisely what allowed me to make the most of it.
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Smartphone App Reviews

Jonathan Dunn, MD, Jacqueline Kraftm MD, and Mitul Kanzaria, MD

Doximity

Heart Failure Trials

Price: Free
Platform: iOS, Android

Price $2.99
Platforms: iOS, Android

What It Does: Doximity is a professional network for
physicians. It offers a comprehensive medical directory with
140,000 doctors. Additionally, the app gives a free fax number
to everyone who joins, allowing you to securely receive medical
records directly into your phone.

What It Does: The app summarizes pertinent trials that are
relevant for the treatment of heart failure. It organizes the trials
by EF, class of medication, and name of medication. It gives
a comprehensive summary of the trial, including methods,
inclusion/exclusion criteria, results and more.

Likes: Allows you to quickly and easily receive medical records
and look up contact info for doctors.

Likes: Well organized, comprehensive.

Dislikes: Not possible to print the records that you receive.

QX Calculate

ECG Source

Price: Free
Platforms: iOS, Android, Blackberry

Price: $1.99
Platforms: iOS
What It Does: This app lists the criteria for different EKG
diagnoses and provides a full searchable list of ECG
diagnoses and criteria. It also has many sample EKG’s, a quiz
and video tutorials.
Likes: Good reference app.
Dislikes: Videos are too simplistic and the quiz only offers
4 sample questions.

GoodRx
Price: Free
Platforms: iOS, Android
What it Does: This app enables you to find out the price of any
medication without insurance at local pharmacies.
Likes: Enables providers to find affordable medications for
patients.
Dislike: Some prices reflected are after a coupon associated
with the app, although these can be printed for patients on
the GoodRx website.

“Spare Change”
photograph by Sara Shultz

52

Dislikes: Possibly too advanced for medical students.

What it Does: This app provides a repository of calculators,
equations, and scores that are split by specialty.
Likes: Easy to use calculators while on rounds.
Dislike: Can be hard to find certain calculators.
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